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In the past several years, advances in high-throughput DNA sequencing have enabled
massive tumor genome sequencing studies to identify recurrent mutations across many dif-
ferent cancer types and thousands of patients. These mutational surveys have reinforced the
paradigm that cancer is a “disease of the genome” through the identification of inactivat-
ing mutations in well studied tumor- suppressors and activating mutations in well studied
oncogenes, particularly in adult cancers. A new class of recurrent mutations has emerged as
well, inactivating genes that encode chromatin regulators; these are disproportionately preva-
lent in pediatric and hematological malignancies. The molecular consequences of chromatin
regulator mutations on a genome-wide scale, and moreover, how other genetic insults drive
chromatin dysregulation and potentially enhance tumorigenesis, were until now completely
unknown. In the chapters that follow, we show that a translocation-derived transcription fac-
tor chimera in Ewing Sarcoma acquired chromatin modifying activity such that it acts as a
pioneer factor, altering chromatin configuration and inducing transcriptional dysregulation.
We also demonstrate how alterations in chromatin link aberrancies in transcript processing
with histone methyltransferase loss in clear cell Renal Cell Carcinoma through functional
studies of chromatin accessibility and RNA processing in primary human tumors. Lastly, we
describe how simple modifications to our experimental assay of chromatin accessibility permit
the usage of archival (FFPE) human specimens. Together, in addition to contributing a greater
understanding of chromatin biology and dysregulation in human cancers, this work will en-
able large-scale studies of the causes and roles of chromatin dysregulation in other models of
human disease. It has also led to the initiation of high-throughput screens for compounds that
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affect chromatin accessibility, and subsequently tumor cell proliferation. Future work will uti-
lize chromatin accessibility information as a novel clinical diagnostic and prognostic to guide
and enhance patient treatment.
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Over the course of the last decade, since the completion of the sequencing of the hu-
man genome, significant technological advances in DNA sequencing have fueled a revolution
in genomics with widespread implications for studies of human health and disease. High-
throughput DNA sequencing was introduced in 2005–2007 [1] [2], and since then, the cost
of DNA sequencing per megabase has fallen by over four orders of magnitude, far exceeding
the rate predicted by Moore’s Law. Coupled with both previously known and novel molecular
biological techniques, such as chromatin immunoprecipitation (ChIP) [3] [4] [5] [6], DNase
hypersensitivity [7] [8], micrococcal nuclease (MNase) digestion [9], Formaldehyde-Assisted
Isolation of Regulatory Elements (FAIRE) [10], bisulfite (BiS) conversion [11], RNA im-
munoprecipitation (RIP) [12], and others [13], high-throughput sequencing has since been
used extensively to study gene expression and its many regulatory processes in human cell
lines and tissues. Large consortia such as ENCODE, The Cancer Genome Atlas (TCGA),
and the Epigenome Roadmap have generated an enormous wealth of sequencing-based data,
much of which is now available to the scientific community. Despite their goals being rooted
in basic research, these consortia, as well as various groups utilizing their data, have begun to
examine the processes that govern human health and those that underlie disease (e.g. [14] [15].
The entire field of medicine, particularly oncology, is thus on the verge of a metamorphosis in
which genomic technologies guide patient diagnostics, prognostics, and therapy.
1.1 Initial discoveries from tumor genome sequencing
The Cancer Genome Atlas, the International Cancer Genome Consortium, and others have
now cataloged the frequencies and types of mutations in many different cancer types and
subtypes across thousands of patients [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26].
Many of the results have been predictable though nonetheless useful. One such finding is
that cancers with a clear link to mutagenic exposure such as melanoma, lung squamous cell
carcinoma, and lung adenocarcinoma often have genomes with tens of thousands of mutations
in coding and non-coding space, large aberrancies in copy number, and catastrophic large- or
small-scale genetic insults such as chromothripsis or kataegis, respectively [25] [26]. This
high mutation rate observed is often coupled with DNA replication or repair defects [25] [26].
Another such finding is that there are recurrent activating mutations in well-studied oncogenes
(e.g. Ras, Raf, SRC, EGFR, MYC, etc) and inactivating mutations in well-studied tumor
suppressors (e.g. TP53, CDKN2A, PTEN, RB1, etc) [25]. These mutations were discovered in
the 1970s and 1980s because they are not only prevalent among many cancer types, but also
can directly cause oncogenic transformation of normal cells (reviewed in [27]).
The derangement of cellular signaling, for example through oncogene activation, also has
prominent effects at the level of transcription (e.g. [28]). Differences in transcript abundance
can be exploited to sub-classify tumors into groups that demonstrate differences in patient
outcome or therapeutic response. Breast carcinomas, for example, can be subclassified into
subtypes based on their transcriptional profiles [29] [18]. Similar analysis of glioblastomas
revealed four tumor subtypes, each of which have transcriptional differences likely driven
largely by mutations in TP53, PDGFRA, NF1, or PTEN [30]. Together, oncogenic activation
and/or tumor suppressor silencing and the observable defects in cell signaling, transcription,
and cell proliferation have reinforced the paradigm that cancer is a “disease of the genome”.
Tumor genome sequencing has also yielded a number of surprising results. Most notably, a
new class of mutations have been found in genes that encode proteins involved with chromatin
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remodeling or modification of histones or DNA (e.g. PBRM1, SMARCB1, ARID1A, SETD2,
MLL2, DNMT3A, UTX, etc), or encode histone core proteins themselves or their variants
(e.g. H3F3A) [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43]. The advent
of high-throughput sequencing allowed for the discovery of mutations in a tumor genome
in two weeks or less, but prior to the studies described here, no comprehensive analysis of
the molecular consequences of chromatin regulator mutations has been performed in human
tumors.
1.2 Chromatin structure, histone modifications, and regulation of gene expression
The genomes of eukaryotic organisms are packaged into a structure known as chromatin.
This packaging allows for the approximately 2 meter long DNA polymer to fit within a 2-
micron nucleus. This packaging is achieved by wrapping the DNA double helix approxi-
mately twice (147 bp) around an octamer of histone proteins, consisting of two copies each
of histone proteins H2A, H2B, H3, and H4 [44]. This repeating functional unit of chromatin,
in which DNA is complexed with histone proteins, is known as the nucleosome core particle.
Nucleosomes are further coiled and compacted to form the 30 nm fiber, a solenoidal structure
that is further compacted to form the mitotic chromosome [45].
The regulation of chromatin structure and DNA-templated processes such as transcrip-
tion is tightly orchestrated. The binding of sequence-specific regulatory proteins including
transcription factors is affected by chromatin organization. Displacement, destabilization, or
repositioning of nucleosomes is, in many cases, a necessary precursor to the binding of such
regulatory factors (e.g. [46]), and may influence the modulation of gene expression. In addi-
tion to positioning of nucleosomes themselves, modification of the tails of histones H3 and H4
can influence transcription factor binding and activity. Histone tails can be methylated, acety-
lated, phosphorylated, ubiquitylated, and/or otherwise decorated by many post-translational
modifications [47] [48]. Nucleosomes may also carry histone variants, which together with
post-translational modifications can lead to changes in nucleosome stability [49] [50] [51].
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Histone modifications and variants are often heritable across generations, therefore are fre-
quently classified as “epigenetic” alterations, although this designation is controversial [52].
Each modification and variation alters nucleosome stability or functions to roughly divide
the genome into active, recently active, poised, or repressed states (e.g. [53]). Many such
regions of the genome are demarcated differentially by histone modifications or exhibit al-
tered nucleosome occupancy across cell types in a way that corresponds to cell-type-specific
gene expression [53] [14] [15] [54] [55]. Each of these dynamic processes are carefully con-
trolled by histone methyltransferases and demethylases, histone acetylases and deacetylases,
and chromatin remodelers (reviewed in [55]).
1.3 Epigenetics of cancer
Many forms of cancer are now known to contain mutations in chromatin regulators. It
has been suggested that alterations at the level of chromatin resulting from these mutations
may play a prominent role in oncogenesis [32], may confer differences in patient survival,
or may associate with more advanced disease [56]. To investigate whether the prevalence of
chromatin regulator mutations was uniform across cancer types, we mined data from numer-
ous large-scale tumor-sequencing projects, as well as other primary publications and databases
for 22 different cancer types (rhabdoid, neuroblastoma, medulloblastoma, Acute Lymphoblas-
tic Leukemia, Ewing Sarcoma, glioblastoma multiforme, clear cell Renal Cell Carcinoma,
melanoma, lung adenocarcinoma, Acute Myeloid Leukemia, esophageal adenocarcinoma,
lung squamous cell carcinoma, Chronic Lymphocytic Leukemia, as well as tumors of the
cervix, thyroid, breast, ovary, prostate, colon/rectum, stomach, pancreas, and bladder) [16]
[18] [17] [19] [20] [21] [22] [23] [24] [25] [26] [57] [58] [59] [60] [61], SEER. We compared
the median age of cancer onset and the median number of coding mutations per megabase of
exome (“mutational load”) in the cancers. We also computed what we refer to as the “epige-
netic load”, which is the frequency at which a chromatin regulator mutation appeared in the
five most abundant mutations for a particular cancer, normalized by the total mutational load
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for that cancer. These data illustrate that a new paradigm is emerging: pediatric and hema-
tological cancers carry a surprisingly low mutational load, and those mutations that do occur
are disproportionately prevalent in chromatin regulators. (Figure 1.1). The presumed effects
on chromatin therefore suggest that these tumors can be categorized by being a disease of the
genome, and also more specifically a disease of the epigenome. There was one exception to
the group of pediatric tumors: Ewing Sarcoma. This is likely due to the unique mechanism of
carcinogenesis in that cancer, which is caused by expression of a translocation product (EWS-
FLI; discussed in Chapter 2 [57]). Other cancers carrying translocations that form chimeric
DNA-binding factors, including prostate cancer and various forms of leukemia, may thus also
exhibit alterations in chromatin structure.
Mutations in chromatin regulators, though prevalent in pediatric malignancies, are also
present in many if not all of the adult cancers but typically at lower frequency; one notable
exception is clear cell Renal Cell Carcinoma. It is not yet well understood which class of
mutation occurs first in these contexts. It has been suggested that epigenetic alterations, such
as the loss of DNA methylation, may lead to additional mutations due to genomic instability
[62] or induced plasticity in cellular differentiation [63]. Therefore, one possible theory may
be that mutations in chromatin regulators arise at an early age. Sometimes these mutations re-
sult in pediatric malignancy if they occurred in a particularly susceptible cellular niche. Other
times, however, these mutations may initially contribute only subtly to changes in cellular
processes but create an environment in which many more mutations can accumulate over the
course of many years. This theory could offer an explanation for the higher mutational load
in adult cancers, particularly those without known associations with mutagenic exposure.
1.4 Isolation of active regulatory elements from human chromatin
Elucidating the functional consequences of mutations in genes encoding chromatin reg-
ulatory proteins in human tumor specimens requires the application of techniques initially
developed for cultured cells. Chromatin accessibility is characterized by the displacement or
5






































Figure 1.1: Disproportionate frequency of chromatin regulator mutations in pediatric and
hematological cancers. The median age of onset (x-axis) is plotted against the median number
of coding mutations per megabase of exome (“mutational load”, y-axis). Points are colored
based on their “epigenetic load”, computed as the frequency at which a chromatin regulator
mutation appeared in the five most abundant mutation types for a particular cancer, normalized
by the total mutational load for that cancer.
destabilization of nucleosomes from chromatin through the action of transcriptional regula-
tors. The isolation of nucleosome-depleted regions (“open chromatin”) thus identifies func-
tional gene regulatory elements across the genome. Open chromatin has traditionally been as-
sayed via preferential digestion by nucleases such as DNase I [64] [65] [66] [67] [68] [69] [70]
[71]. An alternative methodology for the isolation of regulatory elements is termed FAIRE
(Formaldehyde-Assisted Isolation of Regulatory Elements) [10] [15] [72] [73] [74] [75]. The
technique has now been used in a wide range of eukaryotes, from Plasmodium [76] to maize
[77], and we recently demonstrated its efficacy in the Kaposi Sarcoma-associated Herpesvirus
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[78]. We have now extended the FAIRE technique to permit studies of chromatin accessibil-
ity in both primary human tissues and tumors as well as Formalin-Fixed Paraffin-Embedded
(FFPE) tissue specimens.
1.5 Epigenetic therapies in cancer
Cancers can be treated by compounds that act through chromatin or DNA-modifying en-
zymes such as inhibitors of DNA methylation and histone deacetylases. Trapoxin, and vari-
ants thereof, as well as other compounds have been known since 1996 [79] to inhibit histone
deacetylase activity [80], and inhibitors of DNA methylation (such as 5-azacytidine) were
first synthesized in 1974 [81]. More recently, novel classes of histone deacetylase inhibitors,
histone methyltransferase inhibitors (e.g. EPZ-004777 against DOT1L [82] and EPZ-6438
against EZH2 [83]), DNA methyltransferase inhibitors, and bromodomain inhibitors (e.g. JQ1
against BRD4 [84], have proven effective in certain cancer contexts. This exciting new wave
of small molecule inhibitors will provide novel therapeutic options, especially when used in
conjunction with other vetted compounds, for many forms of cancer. It will be of great im-
portance to study the effects of these compounds on the epigenome itself in cancer cells in the
development of specific biological therapies that target chromatin.
1.6 Thesis contributions
The experiments described here show that transcription factor chimerism leads to chro-
matin dysregulation in Ewing Sarcoma (Chapter 2), that mutations in chromatin regulatory
proteins can lead to changes in chromatin accessibility and widespread RNA processing de-
fects in clear cell Renal Cell Carcinoma (Chapter 3), and that modifications to the FAIRE pro-
cedure make this technique compatible with archived clinical specimens and tissue biopsies
(Chapter 4). The ability to assay chromatin accessibility in archival specimens will allow us
to follow the effects of cancer therapies longitudinally in single patients, perform large-scale
studies of rare diseases, and perhaps lead employment of FAIRE as a high-throughput clinical
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diagnostic. Moreover, these data have enabled high-throughput screens for compounds that af-
fect chromatin accessibility, and contribute generally to a greater understanding of chromatin
biology and dysregulation in human cancers (Chapter 5).
This work has been a highly collaborative effort. In Chapter 2, all ChIP experiments,
Western blots, gene expression microarrays, viral-mediated knockdown/re-expression exper-
iments, and quantitative PCR was performed by Mukund Patel and Andrew McFadden. I
performed all computational analyses and interpretation of high-throughput sequencing data
as well as all FAIRE experiments.
In Chapter 3, Kate Hacker prepared all RNA for sequencing, analyzed and interpreted data
from tissue microarrays, performed all altered splicing validation, functionally annotated all
SETD2 mutations, prepared many libraries for high-throughput sequencing, and contributed
significantly to biological interpretation of the data. Darshan Singh analyzed TCGA RNA-
seq data for altered splicing and Joel Parker analyzed genotyping data from our tumor cohort
for mutations. I performed all FAIRE and genotyping experiments, prepared many libraries
for high-throughput sequencing, analyzed all FAIRE and RNA data, developed the Intron
Retention Score and hierarchical clustering methods, analyzed H3K36me3 ChIP-seq data and
TCGA DNA methylation data, and led the integration and biological interpretation of the data.
In Chapter 4, I performed all experiments and analyzed all of the data.
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CHAPTER 2
TUMOR-SPECIFIC RETARGETING OF AN ONCOGENIC TRANSCRIPTION
FACTOR CHIMERA RESULTS IN DYSREGULATION OF CHROMATIN AND
TRANSCRIPTION
2.1 Introduction
Recurrent chromosomal translocations have been associated with an increasingly wide
range of human cancers. Commonly involving genes encoding transcriptional regulators,
translocations can deregulate gene expression and generate structurally novel oncogenic fu-
sion proteins [85]. The transforming activity of these chimeric genes typically reveals cell
type specificity, suggesting that certain lineages are permissive for transformation. Studies
of oncogenic transcription factors have typically focused only on the fusion products or their
target genes and often in heterologous cells, limiting insights into the relative influence of
chimerism and cell lineage.
Ewing Sarcoma, a bone tumor of children and young adults, is characterized by transloca-
tions that fuse a member of the TET family to a member of the ETS transcription factor family
[86] [87] [88]. Identified in 80–85% of Ewing Sarcoma, t(11;22)(q24;q12) results in an in-
frame fusion of EWSR1 to FLI1 [86]. EWS-FLI has been shown to be a potent transcriptional
modulator critical for transformation [89] [90]. Structure-function experiments have demon-
strated that the EWSR1 domain contributes transactivation activity whereas the FLI1 domain
directs DNA binding, and both are required for transformation [91] [92]. EWS-FLI mediates
oncogenesis by directly or indirectly regulating genes necessary for transformation. Despite
evidence that EWS-FLI is necessary for transformation, ectopic expression of EWS-FLI fails
to activate similar genetic programs or transform most human cell lines, indicating that cell
specificity is a major determinant of EWS-FLI activity [93] [94] [95].
FLI1, a member of the ETS family, is an important developmental transcription factor
[96]. FLI1 deletion in mice results in embryonic death from hemorrhage associated with aber-
rant hematopoiesis and vasculogenesis, supporting a role in endothelial development [97] [98]
[99]. Translocations involving ETS members have been implicated in other cancers, including
prostate adenocarcinoma [100]. The function of EWSR1 is less well-understood, however, re-
ports suggest participation in transcription or RNA splicing [101]. EWSR1-deficient mice die
prior to weaning and show defects in B-cell development and meiosis [102]. Other translo-
cations involving EWSR1 have been identified, resulting in chimeras with ATF1 and WT1
in Clear Cell Sarcoma and Desmoplastic Small Round Cell Tumors, respectively [103] [104]
[100].
To characterize the changes in genomic localization and transcriptional output due to
chimerism, we compared EWS-FLI with FLI1 in Ewing Sarcoma and human primary en-
dothelial cells. We integrated genomic targeting with gene expression profiling and found
that in tumor cells, EWS-FLI associated with distinct genomic regions lacking canonical ETS
binding sites and activating a set of genes associated with a transformed phenotype. However,
in endothelial cells, genomic targeting and gene regulation were similar to that of FLI1. We
then examined the influence of epigenetics on this differential targeting by analyzing nucleo-
some occupancy and histone modifications. We found that in Ewing cells, EWS-FLI-targeted
sites exhibited features characteristic of enhancer elements and were bound by RNA Poly-
merase II. Moreover, EWS-FLI silencing resulted in increased nucleosome occupancy of these
regions. In endothelial cells, this same set of regions are normally associated with repressive
chromatin, but become nucleosome depleted upon EWS-FLI expression. These data establish
EWS-FLI as a pioneer factor capable of inducing and maintaining epigenetic reprogramming.
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2.2 Results
2.2.1 Chimerism and cell lineage influence genomic targeting
To compare EWS-FLI with its parental protein FLI1, we developed a lentiviral delivery
approach that permitted concurrent silencing of endogenous EWS-FLI or FLI1 and expres-
sion of an epitope-tagged version of EWS-FLI or FLI1 (Figure 2.1A). Lentiviral knockdown-
replacement was performed in a Ewing Sarcoma cell line (EWS502) and primary human en-
dothelial cells (HUVEC). HUVEC were selected as they abundantly express FLI1, and FLI1
has been implicated in endothelial development [98] [105] [99]. Genomic localization of
each protein was examined by chromatin immunoprecipitation followed by next-generation
sequencing (ChIP-seq). Gene expression was also examined using exon microarrays. The
lentiviral knockdown-replacement strategy offered a number of experimental benefits to facil-
itate comparative genomic analyses. First, viral transduction enabled the titration of protein
expression, avoiding overexpression while achieving efficient knockdown (Figure 2.1B). Sec-
ond, expression of a shRNA directed to the 3′ UTR of FLI1 (able to target both endogenous
EWS-FLI and FLI1 but not the transduced genes which do not contain the 3′ UTR) in all ex-
perimental conditions minimized the possibility for the detection of off-target effects. Finally,
the use of a common and robust antibody for chromatin immunoprecipitation circumvented
issues of antibody sensitivity, specificity, and antigenic variability, factors that can complicate
downstream comparisons, as recently demonstrated [106].
EWS-FLI and FLI1 were expressed to approximate endogenous protein levels in both cell
types (Figure 2.1B). We examined cell proliferation after EWS-FLI knockdown in the pres-
ence or absence of ectopically expressed EWS-FLI or FLI1. In the tumor cells, transduced
EWS-FLI, but not FLI1, rescued the growth arrest resulting from endogenous EWS-FLI si-
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requirement of EWS-FLI for cell proliferation [107] [108] [109] [90]. Inhibition of FLI1 ex-
pression or ectopic expression of EWS-FLI did not affect the proliferation of endothelial cells
under the conditions tested (data not shown).
Differential activities of EWS-FLI and FLI1 could result from either of two mechanisms.
The transcription factors could target similar genomic sites due to their common DNA binding
domain but vary in their ability to modulate gene expression. Alternatively, chimerism could
result in genomic retargeting such that differences in transcriptional output would result from
variation in the sites of chromatin association. To test these two hypotheses, we performed
ChIP-seq for EWS-FLI and FLI1 in both EWS502 and HUVEC. Analyzing only high quality,
uniquely aligned reads, sites of genomic enrichment for each factor were determined using the
Zero Inflated Negative Binomial Algorithm (ZINBA), a flexible statistical model that adjusts
for the effects of GC content, mapability, and copy number variation [110]. We identified
7,172 and 13,878 potential EWS-FLI binding regions in EWS502 and HUVEC, respectively.
FLI1 bound 18,958 regions in EWS502 and 39,439 regions in HUVEC (Figure 2.3A). The
greater number of EWS-FLI binding sites identified in this study compared to previous ChIP-
chip and ChIP-seq approaches [111] [112] [113] likely reflects greater sequencing depth and
enhanced antibody sensitivity. Despite the use of different tumor cells, nearly 75% of the sites
previously identified by ChIP-seq [112] overlap the regions bound by EWS-FLI in this study.
Examination of specific genomic loci demonstrated the contribution of chimerism and cell
lineage to targeting (Figure 2.3A–B). For example, a site near NR0B1 previously shown to
Figure 2.1: Experimental schema for lineage-specific transcription factor silencing and ex-
pression. A. Ewing Sarcoma (EWS502) cells and primary human endothelial cells (HUVEC)
were transduced with lentivirus expressing FLI1 3′UTR-directed shRNA and HA epitope-
tagged versions of EWS-FLI, FLI1, or EWSR1. B. Anti-FLI1 or anti-HA immunoblots of
Ewing Sarcoma cells (EWS502) or endothelial cells (HUVEC) demonstrating concurrent si-
lencing and replacement with HA-EWS-FLI (EF), HA-FLI1, or HA-EWSR1 (EWS). Tubulin
serves as a loading control. Asterisks indicate where a background band runs at a similar
molecular weight as endogenous FLI1. C. After EWS-FLI1 silencing alone (Knockdown) or
together with ectopic EWS-FLI1 or FLI1 expression, EWS502 cells were counted. EWS-FLI
expression, but not FLI1, rescues the effect of knockdown on proliferation.
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Figure 2.2: Cell cycle profile of Ewing Sarcoma cells. The percentage of cells in G0/G1,
S, G2-M, or sub-G0 (Sub) based on propidium iodine staining and flow cytometry were cal-
culated for uninfected A673 cells (“control”) and cells in which endogenous EWS-FLI was























































































































Figure 2.3: Chimerism alters ETS-mediated targeting. A–B. Venn diagrams showing the
number of unique and overlapping EWS-FLI and FLI1 binding regions within the same cell
type (A) or across cell types (B). C–D. UCSC Genome Browser screenshots of EWS-FLI
and FLI1 ChIP-seq signal at two genes NR0B1 (B) and EPHA2 (C). Horizontal bars indicate
targeted sites identified by ZINBA. Tag counts are shown in the Y-axis. E. Meta-gene profile
of EWS-FLI and FLI1 ChIP-seq reads. 1 kb upstream of the TSS through 1 kb downstream
of transcriptional termination is represented. F. Percent overlap of ZINBA-identified EWS-
FLI and FLI1 binding sites with major functional genomic features. Genomic distribution of
features (Genome) is shown for comparison.
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be occupied by EWS-FLI [89] [114] [111] [115] was bound by EWS-FLI but not FLI1 in
both cell types (Figure 2.3C and Figure 2.4). In contrast, sites around the ephrin receptor,
EPHA2, revealed a more complex pattern (Figure 2.3D and Figure 2.5). Sites exclusive to one
transcription factor or cell type were identified, as were sites common to both transcription
factors and cell types. Overall, in the tumor cells, 46% of EWS-FLI sites overlap FLI1 sites,
whereas in HUVEC 75% of EWS-FLI sites overlap with FLI1 (Figure 2.3A). Comparing
targeting across cell types, 45% of EWS-FLI and 55% of FLI1 sites were shared between
EWS502 and HUVEC (Figure 2.3B).
Genomic localization was examined by comparing the raw ChIP-seq signal over all genes
(Figure 2.3E). In tumor cells, FLI1 signal was greater at transcriptional start sites (TSS), in
the proximal upstream region, and through the gene body compared to EWS-FLI. Given the
relative absence of EWS-FLI signal at these genic regions, we compared the overall genomic
distribution of binding sites (Figure 2.3F). Again in tumor cells, FLI1 showed greater associa-
tion with promoters and 5′ and 3′ UTRs than EWS-FLI. Compared to FLI1, EWS-FLI bound
more frequently at distal intergenic regions (>60%). Although EWS-FLI and FLI1 shared
occupancy at a high fraction of sites in endothelial cells, EWS-FLI demonstrated slightly less
association with introns and more with intergenic regions than FLI1 (Figure 2.3F). These data
suggest that in both cancer and normal cells, FLI1 targets genic sites, and chimerism leads
to retargeting to intergenic regions. However, chimerism-induced retargeting is significantly
mitigated by cell lineage.
2.2.2 EWS-FLI and FLI regulate divergent gene programs
To explore the transcriptional implications of genomic retargeting, EWS-FLI and FLI1-
associated gene expression changes in both cell types were examined using exon microarrays.
Differentially regulated genes were identified by comparing RNA from cells in which the en-
dogenous transcription factor had been silenced to those expressing either EWS-FLI or FLI1.















































Figure 2.4: The range of factor- and cell-type-specific binding; NR0B1. EWS-FLI (black)
and FLI1 (red) ChIP and input control signal in both Ewing Sarcoma cells and HUVECs at
NR0B1. Viewing range is cut at 50 reads. Horizontal bars represent bound sites as identified















































Figure 2.5: The range of factor- and cell-type-specific binding; EPHA2. EWS-FLI (black)
and FLI1 (red) ChIP and input control signal in both Ewing Sarcoma cells and HUVECs at
EPHA2. Viewing range is cut at 50 reads. Horizontal bars represent bound sites as identified
by ZINBA. Scale bar and schema of each gene are depicted at the top and bottom of the
represented tracks.
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factor expression. Although EWS-FLI occupied fewer genomic sites than FLI1, it modulated
the expression of more genes in both cell types. This difference was greatest in tumor cells in
which EWS-FLI altered the expression of three times as many genes as FLI1 (Figure 2.6A).
Genes regulated by FLI1 were mostly distinct from those regulated by EWS-FLI, with 40–
45% shared in either cell type. However, of the genes commonly modulated by either factor in
HUVEC, 97% were regulated concordantly, whereas in tumor cells, opposing effects on gene
expression were frequently observed (41% of coregulated genes) (Figure 2.6B). Cell-type-
specific regulation was also evident. Only 34% of genes differentially expressed by EWS-FLI
were shared across the two cell types, whereas only 12% of FLI1 differentially expressed
genes were shared.
The classes of genes regulated by EWS-FLI and FLI1 also differed significantly (Figure
2.7). Approximately one-third of the genes modulated by EWS-FLI in tumor cells were im-
plicated in cancer or cell cycle regulation; the identification of these categories supports of
previous studies of gene regulation by EWS-FLI [116] [90] [95] [117]. In contrast, FLI1 ex-
pression in tumor cells induced genes associated with hematopoiesis, hematological system
development and function, and cellular development, including genes of the ephrin, thrombin,
and relaxin signaling pathways. In endothelial cells, similar gene ontologies were modu-
lated by both transcription factors. These data suggest that cell type influences the impact of
chimerism on transcriptional output.
2.2.3 Differentially targeted regions are marked by DNA sequence and regulatory variation
Since genomic sites of EWS-FLI and FLI1 occupancy were mostly distinct, we hypothe-
sized that additional factors might specify EWS-FLI or FLI1 targeting in a transcription factor-
or cell-type-specific manner. We employed a computational strategy that selected binding sites
that most discriminated transcription factor or cell type and then performed hierarchical clus-
tering using the normalized ChIP-seq signals for each region (Figure 2.8A). Six major clusters
of binding sites emerged. These clusters exhibited both transcription factor- and cell-type-
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Figure 2.6: Differentially expressed genes in endothelial and Ewing cells. A. Number of up-
and down-regulated RefSeq genes identified in each cell type for each transcription factor.
B. Fold-change of genes commonly differentially expressed in EWS502 (blue) and HUVEC
(red) cells by EWS-FLI or FLI1. Numbers shown represent gene counts per quadrant.
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Figure 2.7: EWS-FLI and FLI1 differentially expressed genes have distinct biological func-
tions. A. Over-enriched biological functions and B. Over-enriched biological pathways iden-
tified by Ingenuity Pathway Analysis indicate that EWS-FLI activates cancer-related genes
and pathways, while FLI1 activates genes involved in normal endothelial growth in both cell
types. Significance line (p < 0.05) is drawn in red.
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dependence, with cell type being the primary determinant for the majority of differentially
bound sites. Sites in clusters 1–3 revealed higher signals in tumor cells whereas those in clus-
ters 4–6 (representing 74% of the sites) were enriched in endothelial cells. The finding of
HUVEC-specific clusters bound by both EWS-FLI and FLI1 further supports that in a normal
cellular environment these transcription factors share similar targeting.
Testing for associations between each cluster and gene expression demonstrated that sites
in clusters 5 and 6 tended to be located near the union set of differentially expressed genes
from both cell types (Figure 2.8B). Approximately 15% of differentially regulated genes con-
tained at least one of these sites within 25 kb. Furthermore, genes that contained a TSS flanked
by a site in clusters 5 or 6 (within 25 kb) were significantly more likely to be regulated by the
expression of either EWS-FLI or FLI1 in HUVEC (Figure 2.8C). Genes harboring cluster 6
sites were frequently upregulated (82% and 88% for EWS-FLI and FLI1, respectively), how-
ever, genes proximal to cluster 5 sites lacked this skew toward upregulation. Interestingly,
these data suggest that although FLI1 targets both cluster 5 and 6 sites equally, the potential
occupancy of EWS-FLI at these sites characterizes functionally distinct elements. Since the
sequence composition of clusters 5 and 6 were indistinguishable (see below), it is possible
that chromatin differences that permit EWS-FLI binding also favor enhancer activity.
Using the Genomic Regions Enrichment of Annotations Tool (GREAT; [118]), we ob-
served that regions defined by these clusters were strongly associated with specific biologi-
cally relevant ontologies independent of our gene expression data (Figure 2.10). In support of
a direct regulatory role, EWS-FLI-specific binding sites (clusters 1 and 2) were significantly
associated with genes regulated in cells engineered to express EWS-FLI. Interestingly, cluster
2 which demonstrated binding in both HUVEC and EWS502 was associated with genes in-
volved in mesodermal and craniofacial development whereas sites in clusters 5 and 6 (specific
for HUVEC), were largely associated with genes known to play roles in vascular development




















































   












































































































































































































ontology influences genomic targeting and corroborate our expression-based gene ontology
observations (Figure 2.7).
To identify features of the differentially bound regions, comparative de novo motif detection
for each cluster was performed using the 200 bp region surrounding the maximal signal for
each region [119]. Identified motifs were matched to known motifs in TRANSFAC using
TOMTOM [120]. 94% of sites in clusters 1 and 2, which exhibited an EWS-FLI-specific
pattern in the tumor cells, contained a tetranucleotide repeat harboring the core of the ETS
binding site (Figure 2.8D and see below). Sequence elements identified in clusters 3–6 were
more highly varied commonly containing the canonical ETS motif.
2.2.4 Chimerism retargets EWS-FLI to tandem tetranucleotide repeats
De novo motif detection on the sequences uniquely bound by EWS-FLI in sarcoma cells
represented in clusters 1 and 2 identified a GGAA-containing tetranucleotide microsatellite
repeat. EWS-FLI binding to these sequences had been observed in recent studies [111] [112]
[113]. The number of tandem repeats bound by EWS-FLI was higher than expected by chance
in both cell types, although tumor cells demonstrated greater enrichment (Figure 2.9A). Ex-
amination of perfect sequential repeats revealed maximum enrichment at approximately 14
Figure 2.8: Hierarchical clustering identifies cell- and transcription factor-specific variation in
genomic targeting. A. Hierarchical clustering of 6,525 binding sites that exhibited the widest
variation in signal across transcription factors or cell types. Each row was median-centered
and colored based on the average read count across the region. B. Distance (bp) from the
transcriptional start site of the union set of differentially expressed genes to the closet site
from clusters 1–6. C. Number of EWS-FLI or FLI1 differentially expressed genes in HUVEC
containing a cluster 5 (left) or cluster 6 (right) site within 25kb of its TSS, compared to 10,000
permutations of all RefSeq genes. D. Normalized log2 ChIP-seq signal around the midpoint
of identified de novo transcription factor motifs derived from the sequences underlying sites
in each cluster. Clusters 1 and 2 were merged for the composite GGAA microsatellite motif
(1,362 rows). Clusters 3–6 were merged for ETS (682 rows), ETS-AP1 (2,780 rows), AP1
















































































EWS-FLI-bound GGAA Repeats EWS-FLI-bound non-GGAA Repeats EWS-FLI-unbound GGAA Repeats
Figure 2.9: EWS-ETS fusions target GGAA-containing microsatellite repeats. A. Tandem
GGAA repeats identified in EWS-FLI and FLI1 binding sites in EWS502 and HUVEC were
compared to those detected by 1000 permutations of the identical number of regions over the
mappable genome, maintaining chromosomal distribution. All lengths exceeding one repeat
were significant to p < 0.0001. To permit plotting lengths for which the permuted value was
zero, 0.1 was added to each observed and expected value. B. The lengths of repeat regions an-
notated by RepeatMasker bound by EWS-FLI in EWS502 were compared to those unbound in
mappable regions of the genome. Regions bound by EWS-FLI contained significantly longer
repeats as measured by t-test. C. ChIP-qPCR on chromatin isolated from EWS502 cells ex-
pressing the various Ewing Sarcoma fusions. Results are shown as a percent of input control.
Overall, greater binding is identified to EWS-FLI bound regions near differentially expressed
genes that contained GGAA repeats (NR0B1, CAV1, GSTM4, JAK1, IGF1) compared to those
that bound EWS-FLI but did not harbor a repeat (NKX2-2, KIF14, JAK1, CDKN1A, MDM2).
Five control repeat-containing regions are included, and error bars represent standard error of
three replicates. (Inset) Western blot showing exogenous expression of HA-EWS-FLI, HA-
FUS-ERG, and HA-EWS-ERG in EWS502 cells. Tubulin serves as a loading control.
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tandem elements. Periodicity in the length of enriched repeats was observed with a prefer-
ence for 8, 12 and 14 repeat units. GGAA-containing repeats as annotated by RepeatMasker
that were bound by EWS-FLI in EWS502 were significantly longer than those not bound,
with a median length of 100 bp (Figure 2.9B). The difference in lengths reflects the analysis
of either perfect or imperfect repeats. Unexpectedly, FLI1 also bound these repeats, although
with much lower frequency in both cell types, suggesting that the ability to target these sites
is not exclusive to EWS-FLI but rather reflects the enhancement of a native characteristic.
We directly compared the binding of EWS-FLI and other fusions characteristic of Ewing
Sarcoma at the tetranucleotide repeat-containing sites with sites containing the canonical high
affinity ETS motif. The TET-ETS fusions EWS-ERG and FUS-ERG [87] [121] were epitope-
tagged and expressed at similar levels as endogenous EWS-FLI in conjunction with EWS-FLI
silencing (Figure 2.9C, inset). All fusion proteins tested demonstrated a greater enrichment
at sites containing tandem repeats than canonical high affinity sites (Figure 2.9C). These data
corroborate EWS-ERG ChIP [113] and support the general property of TET-ETS fusions to
occupy these elements in a chromatinized genomic context. Moreover, the data suggest that
repeat-containing sites are more likely to be bound than the canonical sites.
In light of recent studies suggesting a length requirement for microsatellite enhancer func-
tion [114] [111], we examined EWS-FLI and FLI1 sites containing five or more repeats.
Approximately 30% of regions uniquely bound by EWS-FLI in either cell type contained
these long tandem repeats, whereas they were present in only 0.2% and 0.04% of regions
unique to FLI1 in EWS502 and HUVEC, respectively. In agreement with the previous stud-
ies, we found that these GGAA repeats were more proximally located to genes upregulated
Figure 2.10: Annotation of clusters of binding sites using GREAT shows biologically relevant
associations with ontologies. Only those terms with FDR-corrected q-values more significant
than 10-5 and in the top 5 significant terms are shown. Bars are color-coded by the ontol-
ogy from which they were derived (MSigDB Perturbation, green; Mouse Phenotype, blue;
MGI expression: Detected, red; GO Biological Process, yellow) and statistical significance is
expressed as -log10(q-value).
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by EWS-FLI (Figure 2.11) with FLI1 exhibiting a similar trend (data not shown). FLI1 bound
more proximally to FLI1-modulated genes compared to EWS-FLI around EWS-FLI-regulated
genes (Figure 2.12), suggesting that in the context of chromatin, tetranucleotide repeats may
function primarily as transcriptional enhancers and can be located distally from genes.






















































Figure 2.11: Upregulated genes are closer to EWS-FLI binding sites. Median distance from
TSS of all genes, all differentially expressed, all upregulated, and all downregulated RefSeq
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Figure 2.12: FLI1 binding sites are closer to FLI1 differentially expressed genes. Distance
from the TSS of a gene differentially expressed by FLI1 (blue) or EWS-FLI to the nearest
FLI1 or EWS-FLI binding site, respectively. The fraction of genes containing at least one site
within the denoted distance is presented.
Preference of EWS-FLI for sites containing tetranucleotide repeats may lead to selec-
tion of, extended polymorphic repeats during tumor development such that their actual length
would differ from the reference genome or other cell types. Previous studies that examined
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a small number of randomly selected tetranucleotide repeats failed to demonstrate a differ-
ence between tumor cells and the reference genome [111] [112]. We compared the lengths
of several tetranucleotide repeats occupied by EWS-FLI in tumor cells with the same regions
in HUVEC and the reference genome (hg18). Regions amenable to evaluation were limited
due to the challenges inherent in primer design for repetitive regions. However, one region,
located in an intron of IGF1, exhibited mono- or biallelic presence of a sequence longer than
that predicted by the reference genome in 4 of 7 Ewing cell lines (Figure 2.13A). Sequencing
of this region from EWS502 cells confirmed that the difference resulted from nine additional
repeats (Figure 2.13B). Interestingly, we observed an extremely faint band running at approx-
imately the same molecular size as the expanded region in the pooled endothelial cells. It is
possible that expansion (relative to the reference genome) represents an allelic variant present
in the population.
2.2.5 Combinatorial DNA binding motifs distinguish endothelial cell targeted sites
Canonical ETS motifs were identified in 72% of cluster 3 (which was largely specific
to FLI1 in tumor and endothelial cells) and clusters 4–6 (which specific to endothelial cells
but bound by both proteins) sites. ETS motifs in cluster 3 demonstrate that FLI1 retains the
ability for context-dependent targeting even in sarcoma cells. Strikingly, the motif for the AP1
complex was detected at nearly the same frequency as ETS at cluster 3–6 sites. Remarkably, of
the sites containing a computationally derived AP1 motif, 76% overlapped ChIP-seq-derived
binding sites for c-Jun, a member of the AP1 complex, in HUVEC [122]. In addition to
isolated AP1 motifs, composite ETS and AP1 motifs were observed at approximately 46%
of the sites in clusters 3–6. We explored variation in the spacing between the ETS and AP1
motifs; approximately 25% of the sites revealed separation of 1 bp with spacing increments of
2 to 10 bp each accounting for an additional 9 to 12% of sites. The composite nature of this
ETS-AP1 motif is suggestive of cooperative binding at these sites. The GATA motif was also
observed in approximately 15% of sites from clusters 3–6. The ETS motif found within these
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Figure 2.13: EWS-FLI-bound tetranucleotide repeats demonstrate repeat length polymor-
phism. Length of repeat found within IGF1 across 7 Ewing Sarcoma cell lines (EWS502,
EWS894, A673, MHH-ES-1, RD-ES, SK-ES, SK-N-MC) and compared to endothelial cells
(HUVEC). Lengths determined by PCR using primers flanking repetitive region and resolved
on an 8% acrylamide gel. B. Sequence of repeat region from EWS502 cells compared to refer-
ence genomic sequence (hg18). Multiple sequence alignment was performed using ClustalX
with default parameters. Exact sequence matches denoted by “*”, regions of difference high-
lighted in yellow.
regions, demonstrated context specific sequence variation. ETS sites in isolation typically
contained a C preceding the GGAA core, matching the canonical ETS motif [113]. However,
ETS motifs in composite sites with AP1 were preceded by an A. Similar motif variation had
been observed in the tandem binding sites of ETS-1 with RUNX1 [123].
We then compared the intensity, location, and specificity of regions containing consensus
binding sites by plotting normalized ChIP-seq signals around a union set of sites that share a
specific motif (Figure 2.8D). Tetranucleotide repeats were preferentially and centrally bound
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by EWS-FLI. In the tumor cells, FLI1 demonstrated a modest ability to interact with some
of these sites as previously noted (Figure 2.9A). In endothelial cells, the signal intensities
and positions of FLI1 and EWS-FLI were similar around ETS, ETS-AP1, AP1, and GATA
motif-containing sites. In the tumor cells, FLI1 bound these sites although with far less signal
intensity, again demonstrating the tendency of FLI1 to function normally in tumor cells. Since
de novo motif identification may preclude detection of less common motifs, we examined
signals from HUVEC around sites containing computationally-predicted motifs for Myc:Max,
NFB, STAT, PPAR, HNF4A, and CREB [124]. Although these sites represented less than 1%
of those analyzed, similar patterns of EWS-FLI and FLI1 signal were detected (Figure 2.14).
All motif associations were lost when the sites were permuted (Figure 2.15). These data
suggest a large network of cooperative interactions for FLI1 binding, most frequently AP1
and GATA. Sites selective for EWS-FLI occupancy in sarcoma cells were distinguished in
function, location, and composition from those sites that characterize endothelial targeting.
2.2.6 Epigenetic factors distinguish microsatellite repeats in Ewing Sarcoma
Since cell lineage dominated the variation in targeting of both chimeric and parental tran-
scription factors, we explored features of epigenetics and chromatin configuration that could
underlie these differences. We performed ChIP-seq on Ewing Sarcoma cells for histone marks
associated with active (H3K4me1, H3K4me2, and H3K4me3) or repressed (H3K27me3)
chromatin. We also performed Formaldehyde Assisted Isolation of Regulatory Elements cou-
pled with next-generation sequencing (FAIRE-seq) to identify regions of nucleosome deple-
tion that characterize active regulatory elements. Consistent with other cell types, we found
that both methylation on H3K4 and FAIRE demonstrated a strong association with gene ex-
pression, whereas H3K27me3 was inversely correlated with transcription (Figure 2.16A).
Deregulation of homeobox genes is a common attribute of cancer [125]. We compared





























































































































































Figure 2.14: EWS-FLI and FLI1 occupied similar sites in a normal cellular context. Heatmap
showing normalized ChIP-seq signals of EWS-FLI or FLI1 in both Ewing Sarcoma cells and
HUVECs around computationally predicted transcription factor binding sites of ETS, Max,
NFkB, STAT, PPAR, HNF4, and CREB. Sequence logos corresponding to the computationally
predicted motif are shown on the left. Color was assigned on a log2 scale from 0.5 to 9.
stem cells and HUVEC [122] (Figure 2.17). Interestingly, at the HOXA cluster, we detected
a bivalent signal similar to that observed in embryonic stem cells [126]. At the other HOX
clusters however, there was an overall lack of H3K27me3 and enrichment for H3K4me2 and
H3K4me3. This activation was not specific for a set of homeobox genes, as seen in differ-
entiated cells (HUVEC). Widespread activation across nearly all genes in each cluster may
contribute to the dedifferentiated or more stem-like state of Ewing sarcomas. The loss of
H3K27me3 signal was not observed genome-wide (e.g. PAX2 and WNT3A loci, Figure 2.18).
We focused our analysis on regions containing the tetranucleotide repeats since they rep-
resented the most prominent feature distinguishing EWS-FLI targeting. Comparing the epi-
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Figure 2.15: Permutation abolished EWS-FLI and FLI1 signal enrichment at all identified
sites. One permutation of GGAA repeats, ETS, ETS-AP-1, AP-1, GATA, as well as the 7
computationally predicted motifs presented in Figure 2.14 shows the observed pattern is non-
random. Color was assigned on a log2 scale from 0.5 to 9.
cell lines assayed as part of the ENCODE consortium, we observed that in virtually all cell
types repressive marks were common at microsatellite and other repetitive elements (Figure
2.16B, Figure 2.19) [4] [127] [53]. In Ewing cells, however, strong H3K4me1 and H3K4me2
signals flanked those repeats that were bound by EWS-FLI relative to those that were not
bound although the proportion of active histone marks that directly overlapped repeats was
similar to other cell types (Figure 2.16C and Figure 2.19). Moreover, EWS-FLI-bound sites
were largely devoid of H3K27me3 and were nucleosome depleted. Relative to HUVEC and
control regions, these sites were also bound by RNA polymerase II (Figure 2.16D). To confirm
nucleosome depletion, we also performed pan-histone H3 ChIP, which demonstrated overall
histone H3 depletion at several sites (Figure 2.16D). Intriguingly, other classes of repetitive
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elements were also enriched by FAIRE, including SINEs, LINEs, and other types of simple
and microsatellite repeats (data not shown). Together, these data support the utilization of the
microsatellites as transcriptional enhancers. We also observed a striking difference in DNA
sequence encoded nucleosome occupancy between EWS-FLI and FLI1-bound sites (Figure
2.20). Whereas FLI-bound sequences demonstrated high nucleosome occupancy, a feature of
regulatory elements in higher eukaryotes [128], this pattern was not seen for EWS-FLI-bound
regions, further supporting the unique attributes of EWS-FLI targeted domains.
2.2.7 EWS-FLI targets enhancer like elements altering and maintaining the local chromatin
environment
In addition to analyzing microsatellite regions we also assessed the chromatin structure
and epigenetic status of each class of regions identified by differential chromatin targeting
(Figure 2.8A). These data further support that the Ewing-specific clusters (clusters 1–2) ex-
hibit an epigenetic pattern resembling that of an enhancer element only in tumor cells (Fig-
ure 2.21A). Conversely, the endothelial-specific clusters (clusters 4–6) show an enhancer-like
pattern unique to HUVEC. Distinct from the other clusters, sites in cluster 3, which exhibited
binding by FLI1 in both cell types, were marked by H3K4me3. This epigenetic signature
Figure 2.16: Deregulation of repetitive elements in Ewing Sarcoma. A. Heatmap of normal-
ized ChIP and FAIRE signal 3 kb around TSS ranked by gene expression in Ewing cells.
Color was assigned on a log2 scale of -3 to 3 for ChIP and -6 to 2 for FAIRE. B. Normal-
ized ChIP and FAIRE signals around the centers of GGAA repeats in five ENCODE cell lines
(GM12878, black; HUVEC, red; K562, blue; NHEK, green; H1hESC, orange). Mapability
of the underlying DNA sequence is represented on a scale of 0 (ambiguous) to 1 (unique)
and is plotted in grey. C. Normalized ChIP and FAIRE signals around the centers of EWS-
FLI-bound (left) or -unbound (right) GGAA repeats in Ewing Sarcoma cells. Mapability of
the underlying DNA sequence is represented on a scale of 0 (ambiguous) to 1 (unique) and
is plotted in grey. D. Enrichment of EWS-FLI-bound GGAA repeats for RNA Polymerase
II (left) and histone H3 (right) in Ewing cells (red) and HUVEC (blue), as assayed by ChIP-
qPCR. All values are represented as the fold-change relative to the average of the negative



































































































































Figure 2.17: UCSC Genome Browser snapshots of epigenetic patterns in EWS502 (black),
HUVEC (orange), and H1hESC (green). Three of the four HOX clusters show activation and
aberrant H3K27me3 patterns relative to normal cell types. Values are presented on a scale of
0 to 50 reads.
suggests that FLI1-specific sites tend to be located proximal to transcriptional start sites.
Since EWS-FLI-specific chromatin domains were normally nucleosome occupied in HU-
VEC, we asked if EWS-FLI could directly alter chromatin conformation. EWS-FLI expres-
sion in HUVEC was associated with increased FAIRE enrichment (indicative of decreased
nucleosome occupancy) at some of the closed chromatin domains, relative to control domains
(Figure 2.21A). Moreover, silencing of EWS-FLI in tumor cells resulted in increased nucleo-
some occupancy at all sites tested. These findings suggest that chimerism confers nucleosome
displacement activity, and continued EWS-FLI expression is required for the maintanence
of an open chromatin configuration at these sites. This activity may be mediated through

































Figure 2.18: UCSC Genome Browser snapshots of epigenetic patterns in EWS502 (black),
HUVEC (orange), and H1hESC (green). Normal H3K27me3 at PAX2 (left) and WNT3A
(right), consistent with normal cell types. Values are presented on a scale of 0 to 50 reads.
demethylases.
2.3 Discussion
Lineage-specific outcomes are observed when chimeric transcription factors are expressed
in various cell types, suggesting a major cell-specific influence on activity. One cell type may
be permissive for transformation whereas other cells may not tolerate expression resulting in
growth arrest or apoptosis. Cellular factors that influence activity may not be evident from
studies of transcription factor-chromatin targeting limited to a single transcriptional regulator
in a single cell type.
























































































































































































Figure 2.19: Epigenetics and chromatin accessibility of GGAA microsatellites. Percentage
of GGAA repeats overlapping areas of significant enrichment for H3K4me1, H3K4me2,
H3K4me3, H3K27me3, and FAIRE are presented for EWS502, HUVEC, H1hESC, K562,


































Figure 2.20: Predicted nucleosome occupancy of EWS-FLI and FLI1 binding sites. Average
nucleosome occupancy predicted on DNA sequence [128] surrounding the summits of EWS-
FLI and FLI1 binding sites in EWS502.
parental protein FLI1 in two relevant human cell types, we were able to separate the influence
of chimerism and cell type on genomic targeting and function. In tumor cells, chimerism re-
sulted in genomic retargeting, with approximately 40% of EWS-FLI binding sites containing
a tetranucleotide repeat composed of the core ETS motif. Although FLI1 can bind to these
repeats, the majority of FLI1 sites contained the canonical ETS motif. By contrast, in en-
dothelial cells, targeting of both proteins demonstrated remarkable similarity. EWS-FLI and
FLI1 localized to sites containing the canonical ETS motif as well as sites marked by AP1 and
GATA motifs. Binding to a number of other less common DNA motifs suggests an extended
network of interacting cooperative transcription factors. Given the abundance of ETS motif-
containing sites in the genome, these interactions likely regulate cell lineage-specific patterns
40
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Figure 2.21: EWS-FLI is capable of epigenetic reprogramming. A. Normalized signals for
H3K4me1 (black), H3K4me2 (red), H3K4me3 (blue), H3K27me3 (green), and FAIRE (or-
ange) from both EWS502 and HUVEC are plotted for the 2 kb region surrounding the summits
of sites identified by hierarchical clustering. B. Change in FAIRE enrichment at EWS-FLI-
bound GGAA repeats following EWS-FLI expression in HUVEC. All values are represented
as fold-change relative to scrambled shRNA control. Error bars represent the standard error
from three technical replicates. C. Change in FAIRE enrichment at EWS-FLI-bound GGAA
repeats following EWS-FLI silencing in EWS502. All values are represented as fold-change
relative to scrambled shRNA control. Error bars represent the standard error from three tech-
nical replicates.
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of genomic targeting. Although FLI1 can bind the tetranucleotide repeats both in vivo and in
vitro, in reporter-based assays it fails to show activity these repeats [111] [129] suggesting that
FLI1 requires the cooperation of other sequence specific transcription factors to activate tran-
scription. The association of ETS proteins with AP1 had been observed [130] [131] [132], and
the functional association of EWS-FLI or FLI1 with AP1 and GATA1 has been demonstrated
in cellular transformation and hematopoietic development [132] [133] [134]. However, our
data also suggest selectivity in cooperating transcription factors. Although studies of ETS-1
identified cooperative binding with RUNX1 [123] and PAX5 [135], neither relationship was
evident in this study.
Differential targeting of EWS-FLI was influenced by epigenetic factors. EWS-FLI bound
microsatellite regions in tumor cells that were atypically marked with an enhancer like signa-
ture, bound RNA polymerase II and resided in nucleosome depleted regions. Our data sug-
gest that EWSR1 chimerism conferred nucleosome modification activity to EWS-FLI and is
required for altering the local chromatin landscape resulting in nucleosome depletion or desta-
bilization. However, the observation of widespread FAIRE enrichment of repetitive regions
suggests that other factors may initially create a favorable chromatin arrangement permitting
EWS-FLI targeting, a question currently being explored. The presence of RNA polymerase II
suggests that these regions may be transcribed, a feature recently shown to be common among
human epithelial cancers [136].
This ability of EWS-FLI to alter chromatin structure is similar to that of FOXA1 or GATA-
4, which bind their cognate sites and affect chromatin configuration [137] [138] [139] [140]
[141] [142]. Since EWS-FLI does not contain the conserved motif thought to be required
for core histone interactions, its activity may be mediated through the recruitment of histone
modifying enzymes. This mechanism is reminiscent of that of EVI1 or ZNF274, which can
recruit histone methyltransferases involved in gene silencing [143] [144] and YY1, which can
recruit a histone H4-specific methyltransferase leading to gene activation [145]. Interestingly
ERG, another member of the ETS family has been shown to interact with the protein ESET
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which contains a SET domain and in turn recruits other chromatin remodeling factors such as
HDAC1, HDAC2, and mSin3B [146] [147].
This study demonstrates the prospect of translational cancer genomics. The persistent
“addiction” of the tumor to aberrant transcription offers a unique therapeutic opportunity.
Consequently, genomic dysreguation through EWS-FLI-specific enhancers mediated by novel
chromatin modifying activity offers the potential for targeted small molecule design. Also,
comparative chromatin immunoprecipitation and the comprehensive identification of regula-
tory elements by FAIRE offer strategies to narrow the search space for regions of the genome
that might play a role in tumor development. One such example is the repeat near IGF1 that
is bound by EWS-FLI in cancer cells and differed in length from the reference genome. This
finding suggests that length polymorphisms may influence EWS-FLI targeting and gene reg-
ulation as has been found for the GGAA repeat length polymorphism observed near NR0B1
for which expression correlated with the number of repeats [115]. The identification of an ex-
tended tandem repeat proximal to IGF1 may be of significance for disease development and
treatment, since EWS-FLI-mediated IGF1 expression and signaling has been implicated in
Ewing Sarcoma development [148] [149], and inhibition of IGF1 signaling is being studied as
a potential therapeutic strategy. Such polymorphisms could arise de novo during tumor devel-
opment or represent an allelic selection in individuals, and the observed selection for longer
repeats could represent a mechanism to augment target gene expression. Further work will
be necessary to determine the functional significance of polymorphisms or other mutations on
disease susceptibility, onset, progression, and treatment.
2.4 Methods
2.4.1 Cell culture
EWS502 were cultured in RPMI 1640 supplemented with 10% FBS, HUVEC cells were
cultured in Vasculife Basal Media (Lifeline Technologies) supplemented with 10% FBS. Both
cell lines were maintained at standard growth conditions of 37◦C and 5% CO2.
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2.4.2 Lentiviral knockdown-expression
A short hairpin region complementary to the 3′ untranslated region of FLI1
(5′-TGCCCATCCTGCACACTTACTTCAAGAGAGTAAGTGTGCAGGATGGGCTTTTTTC-
3′ sense strand) together with PCR-generated HA-tagged EWS-FLI, HA-tagged EWR1, and
HA-tagged FLI1 were cloned into pLL5.5 [150]. Lentivirus was produced in HEK293T cells
as described [150]. EWS502 or HUVEC cells were infected with lentivirus in the presence of
polybrene (6 µg/mL) for 3 h after which media was changed. Chromatin or RNA was isolated
at 72 h (see below).
2.4.3 Chromatin Immunoprecipitation (ChIP) and Formaldehyde-Assisted Isolation of Regu-
latory Elements (FAIRE)
Chromatin was isolated and immunoprecipitation was performed as described in [151]
using 2 µg of anti-HA antibody (Abcam ab9110), anti-H3K4me1 (Abcam ab8895), anti-
H3K4me2 (Abcam ab32356), anti-H3K4me3 (Abcam ab12209), anti-H3K27me3 (Millipore
07-449), anti-RNA Pol II (Abcam ab103968, or H3 (kindly provided by the Strahl lab) . Im-
munoprecipitated DNA was prepared for high-throughput sequencing per manufacturer’s rec-
ommendations (Illumina) including DNA purification using AMPure XP beads (Agencourt)
before PCR amplification. Quantitative PCR was performed as described (Absolute SYBR
Green ROX Mix, Thermo Scientific). PCR primers are available upon request. FAIRE was
performed on three independent cell harvests as previously described [73], and isolated DNA
was prepared for sequencing as above.
2.4.4 Quality Control and Reference Genome Alignment
Reads from chromatin immunoprecipitations were aligned to the reference human genome
(hg18) with Bowtie [152] using default parameters, and unambiguously placed reads were re-
tained. Biological replicates were then merged, cross-replicate correlation was assessed, and
reads were extended in silico to a final length of 200 bp. Any extended reads that overlapped
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large-scale repetitive elements were then removed. Reads from FAIRE were allowed to po-
tentially map to up to four genomic locations, but the best scoring alignment was chosen.
Biological replicates were then merged, cross-replicate correlation was assessed, and reads
were extended in silico to a final length of 134 bp. Any extended reads that overlapped large-
scale repetitive elements were then removed.
2.4.5 Peak calling and permutation
Areas of significant enrichment were identified using the Zero Inflated Negative Binomial
Algorithm (ZINBA, [110]). A window size and offset of 250 bp and 50 bp, respectively, were
utilized for EWSR1 and FLI1 and 500 bp and 125 bp for EWS-FLI. In all cases, a mixture
regression model was created using a combination of the input control, GC content, and a
background derived copy number variation model. Windows with q-values exceeding 0.95–
0.99 were considered statistically significant, and peak boundaries were further refined when
necessary. Additional parameters were specified to account for the broad nature of H3K27me3
domains. The percentage of peaks and average signal over a meta-gene were calculated using
CEAS [153] and plotted in R. For analyses of GGAA repeat length, peak coordinates were
permuted 1000 times across the uniquely-mappable genome while maintaining chromoso-
mal distribution using BEDTools [154]. The frequency of tandem GGAA/TTCC repeats was
computed for lengths 1–25 and compared to that of the test peak coordinates to compute a
two-sided p-value.
2.4.6 Hierarchical Clustering and Motif Identification
A union set of all EWS-FLI and FLI1 peaks for each cell type were merged using Galaxy
[155]. For each of the 51,085 regions, we retrieved the average number of sequencing reads
from each experiment and filtered for regions where the standard deviation and interquartile
range exceeded 0.75 and 0.5, respectively. The resulting 6,525 regions were median-centered
and hierarchically clustered using average linkage and Pearson correlation. The resulting den-
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drogram and heatmap were created in Java Treeview [156]. Regions identified by clustering
analysis were narrowed to a refined window immediately around the location of binding by
intersecting the union set of all 200 bp windows around the site of greatest signal (summit).
De novo motif detection was performed using CisFinder [119] using the 200 bp flanking se-
quence as background. Motif heatmaps were created by calculating the input-normalized
number of sequencing reads for each sample in the 2 kb region surrounding each identified
motif location.
2.4.7 Flow Cytometry
48 h after lentiviral infection, Ewing sarcoma cells (A673) were trypsinized and washed
once with PBS then permeabilized and fixed in 70% ethanol. Cells were washed with PBS and
resuspended in PBS with propidium iodide (concentration) and RNase. Cells were analyzed
(CyAn) and the cell cycle profile was quantified (ModFit LT, Verity House).
46
CHAPTER 3
VARIATION IN CHROMATIN ACCESSIBILITY IN HUMAN KIDNEY CANCER
LINKS H3K36 METHYLTRANSFERASE LOSS WITH WIDESPREAD RNA
PROCESSING DEFECTS
3.1 Introduction
Large-scale cancer sequencing studies continue to identify mutations in genes encoding
chromatin regulatory proteins in a wide variety of human cancers. The downstream molecular
consequences of these mutations, however, remain unknown. Clear cell Renal Cell Carci-
noma (ccRCC) is a particularly relevant model for the study of chromatin regulation in cancer
for several reasons. First, relative to mutations in other classes of genes, ccRCC are marked
by frequent mutation of chromatin regulators [42] [32] [157] [158]. Three of the more com-
monly mutated genes in ccRCC include chromatin modifiers SETD2, PBRM1, and BAP1 [42]
[32] [157] [159], suggesting that alterations at the level of chromatin may play a prominent
role in the development of ccRCC [42] [32]. Mutation-associated changes in chromatin or-
ganization may promote oncogenesis in novel ways, and it has been suggested that specific
chromatin regulator mutations may confer differences in patient survival or associate with
more advanced disease [56]. However, the downstream effect of these mutations on tumor
chromatin biology remains unknown. Second, this cancer is tightly associated with a distinct
transcriptional program resulting from the inactivation of the von Hippel-Lindau (VHL) tu-
mor suppressor gene [160] [161] [162] [163]. The loss of VHL results in the stabilization
of hypoxia inducible factors (HIFs), transcription factors that activate a complex program of
downstream targets, including vascular endothelial growth factor (VEGF) and other genes
[164] [165] [163]. Third, besides VHL and chromatin regulators, mutations in other cancer-
associated pathways are generally absent from ccRCC tumors.
Elucidating the functional consequences of mutations in genes encoding chromatin reg-
ulatory proteins on chromatin organization and transcription in human tumor specimens re-
quires the application of techniques developed for cultured cells to primary human tissues.
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) interrogates chromatin ac-
cessibility by isolating nucleosome-depleted regions of DNA [166] [72] [73] [10] [74]. These
regions harbor regulatory elements such as active transcriptional start sites, transcriptional
enhancers, insulators, silencers, and locus control regions [72] [73] [10] [15] [54] [74]. As
a component of the ENCODE project, FAIRE has been used to identify regulatory elements
across a wide range of cell lines [54] [167]. However, the application of FAIRE to primary
human tissue or to explore the association between chromatin and genetic alterations in cancer
has yet to be evaluated.
We modified FAIRE for use on primary human clinical samples to define the chromatin
landscape in a large cohort of ccRCC tumors and matched normal tissues. We identified
tumor- and normal-kidney-specific classes of chromatin accessibility changes, as well as
those associated with chromatin modifier mutations. We focused our study on SETD2, which
trimethylates lysine-36 on histone H3 (H3K36me3) [168] [169] [170] [171] [172] [31]. As-
sociated with the RNA polymerase II complex, SETD2-dependent methylation tends to occur
towards the 3’ ends of genes and over nucleosomes located at exons [171] [173] [174]. SETD2
and H3K36me3 seem to play a role in co-transcriptional RNA processing. In cell-culture-
based studies, silencing of SETD2 or readers of H3K36me3 has been associated with differ-
ential exon inclusion for individual genes [175] [176] and alternative transcription start site
utilization [177]. However, the consequence of SETD2 deficiency on chromatin organization
and RNA processing remains to be explored on a genome-wide scale and in a disease-relevant
model. SETD2 is mutated in approximately 12% of primary human ccRCC tumors and results
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in H3K36me3 deficiency [178]. A similar rate of SETD2 mutation has also been observed in
high-grade gliomas [179]. A recent study of intratumor heterogeneity in ccRCC identified
distinct SETD2 mutations in all subsections of the same tumor suggesting the importance of
disrupting SETD2 function for a subset of tumors [178].
We found that SETD2 mutation was associated with chromatin accessibility differences
preferentially in gene bodies, and these genes frequently exhibited RNA processing defects.
Nearly 25% of all expressed genes demonstrated aberrancies in splicing, including exon skip-
ping, intron retention, and alternative transcription start and termination sites. We observed
that misspliced exons were marked by a striking increase in chromatin accessibility immedi-
ately upstream of the aberrant splice and a loss of nucleosome occupancy directly over the
exon. This study represents the first investigation of chromatin organization in human tumors
to identify the impact of chromatin modifier mutations on the genomic landscape. Under-
standing chromatin dysregulation in cancer may ultimately inform the application of emerging
classes of chromatin-targeted small molecules in renal cancer.
3.2 Results
3.2.1 Differences in chromatin accessibility between tumors and normal kidney tissue corrobo-
rate the underlying role of HIF in ccRCC
We performed FAIRE-seq on 42 primary ccRCC tumor samples as well as uninvolved
matched normal kidney from seven of these patients (Figure 3.1A–B). We identified approx-
imately 11,000 500-bp genomic intervals with differences in chromatin accessibility that dis-
criminated tumors from normal kidney (2-sided t-test, p< 0.01) (Figure 3.2A–B). For approx-
imately 70% of these regions, FAIRE signal was increased in the tumor samples, indicative of
nucleosome depletion. Using hierarchical clustering, three clusters of genomic loci emerged:
two were marked by tumor-specific nucleosome depletion (Clusters 1 and 2), and another
was characterized by nucleosome depletion in normal kidney tissue but not in tumors (Clus-
ter 3). Virtually all tumors exhibited nucleosome depletion at the sites in Cluster 1, whereas
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approximately 50% of tumors demonstrated FAIRE enrichment at regions in Cluster 2.
We then examined each cluster for shared biological associations among the loci and ad-
jacent genes. Regions in each cluster were associated with genes (GREAT, [118]). For sites in
Cluster 1, 2,274 genes were identified, many of which members of several cancer-associated
gene sets. Particularly interesting in the setting of ccRCC, where HIF transcription factor
family stabilization and activation of hypoxia response genes is a central feature of this tumor
type, we found the most significantly associated genes in this cluster were involved in HIF ac-
tivation and hypoxia regulation (Figure 3.2C, full list of associations for each cluster in Figure
3.3). This association was not observed for regions in Cluster 2 or 3 (Figure 3.3). Analysis of
the sequences in Cluster 1 identified several highly enriched Transcription Factor (TF) motifs
[181], including the hypoxia response element consensus binding sequence (Figure 3.2D). We
additionally found that previously identified HIF1A and HIF2A (EPAS1) binding sites [180]
only significantly overlapped loci in Cluster 1 (p < 0.001, Figure 3.2B, E). The detection of
features associated with the hypoxia response through variation in chromatin accessibility is
consistent with the unique link between HIF activity and ccRCC, and these results demon-
strate the ability of FAIRE to detect central biological pathways through the identification
variations in chromatin organization in an unbiased fashion.
3.2.2 SETD2 mutations link H3K36me3 loss with changes in chromatin accessibility
To identify mutations in chromatin modifiers within tumor samples, we genotyped 33
unique ccRCC tumors (from our cohort of 42 above) and the same 7 matched normal kidney
specimens (Figure 3.1A–B). We classified sequence variants based on predicted ability to con-
fer severe protein structural changes, including frameshift, nonsense, and mutations altering
an annotated splice site (“high severity”), as well as missense mutations (“moderate severity”)
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(Figure 3.4A). Approximately half of the SETD2 mutations in these classes were predicted to
disrupt the catalytic SET domain. High- and moderate-severity mutations were also observed
in other domains in SETD2 including the SRI domain, which mediates the interaction with
RNA Polymerase II. A prediction of copy number using the genotyping data also revealed
that with the exception of one tumor (which displayed one high and one moderate severity
mutation) loss of heterozygozity coincided with mutations in SETD2 (Figure 3.6C).
We identified approximately 7,000 500-bp windows exhibiting significant variation in
FAIRE enrichment between SETD2-mutant and SETD2-normal tumors (2-sided t-test, p <
0.01) (Figure 3.4B, Figure 3.1C). In the SETD2-mutant tumors, FAIRE signal at these regions
was most commonly increased (80%), suggesting that SETD2 loss is preferentially associated
with greater chromatin accessibility. SETD2 trimethylates H3K36 typically at gene bodies
[3] [173]. Regions with increased FAIRE signal in SETD2-mutated tumors (one-sided t-test,
p < 0.01) also overlapped gene bodies (49% of sites), most of which (91%) were marked by
H3K36me3 in normal kidney (p < 0.001 relative to permuted control) (Figure 3.5). More
specifically, regions of increased chromatin accessibility associated with SETD2 mutation
were enriched directly over the same domains marked by H3K36me3 (24.5%, p < 0.001
relative to permuted control) (Figure 3.4C). In contrast, the regions with decreased FAIRE
signal showed no association with H3K36me3, and in fact showed a significant underrepre-
sentation relative to permuted control (p < 0.001). As an additional control, we tested for
this association at regions with increased FAIRE signal in PBRM1-mutant tumors, which we
Figure 3.1: Schematic representation of dataset integration and genomic site identification. A.
Flowchart depicting dataset integration utilized for each figure. Datasets are colored in green,
data types in blue, and resulting figures in black. B. Venn diagram depicting how tumors
were utilized for various experimental approaches. C. Venn diagram depicting the intersection
of the RefSeq transcripts, H3K36me3-marked regions and genes with FAIRE enrichment in
H3K36me3-deficient tumors relative to H3K36me3-normal tumors to yield the 6551 genomic
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expected to yield a divergent set of loci. Indeed, areas of increased chromatin accessibility
associated with this mutation were significantly underrepresented at H3K36me3-marked re-
gions (p <0.001 relative to permuted control). Together, these data indicate that regions of
nucleosome depletion associated with SETD2 mutation preferentially occurs at genic sites
normally marked by H3K36me3.
Although SETD2 is responsible for trimethylation of H3K36, other mechanisms may in-
fluence H3K36 methylation status. Moreover, the effects of specific classes of SETD2 mu-
tations in human tumors on H3K36 methylation in RCC are not known. We quantified
H3K36me3 on a tissue microarray (69 tumors, 11 matched normal kidneys) (Figure 3.4D,
Figure 3.1B). Whereas normal kidney samples demonstrated consistent nuclear H3K36me3
signal (Figure 3.4E), tumors displayed a range of staining intensity, with 53% of tumors
exhibiting reduced H3K36me3 intensity. Hereafter, this group of tumors is referred to as
“H3K36me3 deficient.” Each of the eight tumors that contained mutations predicted to affect
SETD2 activity and screened by IHC demonstrated H3K36me3 deficiency (Figure 3.4E). Tu-
mors containing mutations before the SET domain (Q320fs, E978*, and Q1409*) displayed a
complete loss of H3K36me3 signal. However, tumors with SETD2 mutations located within
the SET domain (G1681fs) or in the SRI domain (R2510L) displayed reduced H3K36me3
signal, suggesting that some mutations may cause a partial loss of function. Several tumors (8
of 13) without identified SETD2 mutations also exhibited reduced H3K36me3 signal. SETD2
Figure 3.2: Regions of tumor-specific nucleosome eviction identify the underlying role of
HIF in ccRCC. A. Hierarchical clustering of median-centered FAIRE signal in windows with
significant differences between tumors and normal kidney (2-sided t-test p< 0.01). B. FAIRE-
seq tracks for ccRCC (black) and uninvolved kidney (red) at two loci. ChIP-seq signal [180]
from HIF1A, HIF2A, and ARNT are plotted in blue. C. The top five gene ontology associa-
tions (q < 1 x 10-5) with sites in Cluster 1 are shown. D. Transcription factor binding motifs
enriched in Cluster 1 compared to local background 500 bp flanking windows (> 2.5-fold over
background and present in at least 10% of the Cluster 1 windows). P-values relative to local
background are shown. E. Fraction of HIF1A and HIF2A binding sites [180] that overlap the
loci in clusters 1, 2 and 3 compared to controls where clustering windows were permuted.
Errors bars represent standard deviation (SD).
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Ontology Term Name Hyper FDR Q-Val  
MSigDB Perturbation
Genes up-regulated in MCF7 cells (breast cancer) 
under hypoxia conditions. 1.72E-11
MSigDB Perturbation
Genes up-regulated in response to both hypoxia 
and overexpression of an active form of HIF1A 
[Gene ID=3091]. 5.07E-11
MSigDB Perturbation
Genes up-regulated in MCF7 cells (breast cancer) 
treated with hypoxia mimetic DMOG 
[PubChem=3080614]. 5.93E-10
Pathway Commons HIF-1-alpha transcription factor network 1.51E-08
MSigDB Perturbation
Genes down-regulated in MCF7 cells (breast 
cancer) after knockdown of both HIF1A and HIF2A 
[Gene ID=3091, 2034] by RNAi. 2.28E-07
MSigDB Perturbation
Genes up-regulated in MCF7 cells (breast cancer) 
after stimulation with NRG1 [Gene ID=3084]. 3.48E-07
Mouse Phenotype respiratory system inflammation 1.36931E-06
Disease Ontology neck neoplasm 1.52881E-06
Disease Ontology neck cancer 1.79918E-06
Pathway Commons
Hypoxic and oxygen homeostasis regulation of HIF-
1-alpha 2.61673E-06
PANTHER Pathway PDGF signaling pathway 2.76948E-06
MSigDB Perturbation
Genes down-regulated in MCF7 cells (breast 
cancer) after knockdown of HIF1A [Gene ID=3091] 
by RNAi. 1.262E-05
Mouse Phenotype lung inflammation 2.15588E-05
Mouse Phenotype abnormal kidney excretion 2.26746E-05
MSigDB Perturbation
Genes down-regulated by MYC [Gene ID=4609], 
according to the MYC Target Gene Database. 3.20939E-05






Genes within amplicon 17q21-q25 identified in a











None significant to q < 1 x 10-5
Figure 3.3: Gene ontology associations with sites in Clusters 1–3. The Genomic Regions En-
richment of Annotations Tool (GREAT[118]) was used to analyze the functional significance
of regions identified by FAIRE. Associations with hypergeometric FDR-adjusted q-values less












































































































































































was undetectable by immunohistochemistry in two of these tumors, whereas others exhib-
ited decreased SETD2 mRNA, suggesting alternate mechanisms for H3K36me3 loss (Figure
3.6). We also observed evidence for SETD2 gene hemizygosity in other H3K36me3-deficient
SETD2-normal tumors, suggesting that loss of heterozygosity may contribute to deficiency
in H3K36 methylating activity (Figure 3.6C). Interestingly, one tumor (Tumor 25 in Figure
3.6C) did not exhibit a copy number loss, carried two SETD2 mutations (E1846*, high sever-
ity; I2499S, moderate severity), and showed a moderate H3K36me3 deficiency (an intensity
value of 0.36 in Figure 3.4E). We would thus predict that at least one of these mutations is
hypomorphic, thus explaining the intermediate magnitude of the H3K36me3 deficiency. Sim-
ilarly, we detected two mutations in SETD2 in another tumor (Tumor 3 in Figure 3.6C), which
exhibited a global loss in H3K36me3 staining along with copy number loss. These data sug-
gest that either the tumor cell population was heterogeneous and the remaining allele was
differentially mutated in each population (as was observed in [178]) or that the one remaining
allele was mutated in two locations. Together, these data illustrate that defective H3K36me3
is a common feature of ccRCC and that SETD2 genotype alone underestimates H3K36me3
deficiency.
Figure 3.4: SETD2 mutations link H3K36me3 loss with changes in chromatin accessibility.
A. Schematic representation of SETD2 mutations predicted to have high or moderate severity
on protein structure. B. Hierarchical clustering of median-centered FAIRE signal in windows
with significant differences between SETD2-mutant tumors (red) and tumors without SETD2
mutation (gray) (2-sided t-test p < 0.01). Samples not genotyped are labeled in white. C.
Proportions of nucleosome-depleted loci overlapping H3K36me3-marked regions compared
to loci with permuted genomic coordinates. Errors bars represent SD. D. Representative im-
munostaining of two ccRCC tumor-normal pairs on the tissue microarray. E. Quantification of
H3-normalized H3K36me3 intensity across 11 normal kidney and 69 renal tumors. Mutation
severity (high, red; moderate, green; none, blue) is indicated. Samples with unknown SETD2
mutation status are plotted in white. The threshold for H3K36me3 deficiency was set to the
lowest observed intensity in normal tissue (dashed line).
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3 kb of METAgene
Normal Kidney H3K36me3 ChIP-seq
Figure 3.5: META-gene plot of H3K36me3 ChIP-seq signal from normal kidney. The average
number of reads is plotted across the 3 kb of average gene length, plus 1 kb upstream and
downstream, demonstrating a 3′ bias for accumulation of the H3K36me3 mark.
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3.2.3 SETD2 mutation is associated with DNA hypomethylation proximal to sites of nucleosome
depletion
In many higher eukaryotes, the H3K36me3 mark is recognized by several chromatin read-
ers, one of which is the PWWP domain of the DNA methyltransferase Dnmt3a, resulting in
DNA methylation proximal to the marked histone [182]. Using ccRCC DNA methylation
data from The Cancer Genome Atlas (TCGA), we observed localized changes (p < 0.05)
in DNA methylation, primarily (>70% of probes) DNA hypomethylation, in SETD2-mutant
tumors of the TCGA dataset at nucleosome-depleted regions identified in our SETD2-mutant
tumors (Figure 3.7). These data link changes DNA methylation to sites of nucleosome eviction
and/or loss of H3K36me3 through SETD2 mutation. This result underscores the importance
of H3K36me3 and how its loss may confer a multifaceted alteration in the epigenome.
3.2.4 Intron retention and splicing defects affect a large fraction of genes with altered chromatin
accessibility in SETD2-mutant tumors
H3K36me3 has been previously implicated in RNA processing [175] [183] [176], an as-
sociation not previously examined in primary tissues or in a disease-relevant model. We thus
hypothesized that H3K36me3 deficiency would alter RNA processing and splicing in tumors
specifically at genes with altered chromatin accessibility. To assess total RNA, including pre-
mRNA and non-polyadenylated transcripts, we performed RNA-seq on ribosome-depleted
Figure 3.6: Decreased SETD2 expression in SETD2-normal tumors results in H3K36me3
deficiency. A. SETD2 RNA expression (RPKM) for an H3K36me3-deficient tumor without
SETD2 mutation compared to the average RPKM for H3K36me3-normal tumors. Error bars
represent standard error. B. Representative immunohistochemical staining of SETD2 protein
and H3K36me3 in a genotypically SETD2-normal tumor with H3K36me3 deficiency (bottom
panel) compared to a SETD2-normal tumor with normal SETD2 protein and H3K36me3 levels
(top panel). C. Log-ratio of gene coverage of each tumor over the average of two normal
kidney samples following a log-transformation and mean-centering of the number of reads
mapping to each gene. Significance of the tumor-normal difference was determined using a



























n = 283 tumors
TCGA DNA methylation










































n = 45 probes
SETD2 normal
Figure 3.7: Nucleosome-depleted regions in SETD2-mutant tumors display localized DNA
hypomethylation. Median-centered DNA methylation intensity for probes in genes both dis-
playing FAIRE enrichment associated with SETD2 mutation and marked by H3K36me3 in
normal kidney. Data from 283 TCGA ccRCC tumors at 157 probes are presented. Specific
hypomethylation of a cohort of these regions was selectively associated with SETD2 mutation.
Color was assigned on a scale of -0.5 to 0.5.
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RNA from 33 tumors, all but one of which was annotated with mutational status (Figure 3.4
and Figure 3.1); six tumors without H3K36me3 status assessed by immunohistochemistry
were omitted. We observed that H3K36me3-deficient tumors displayed a striking enrichment
of intronic pre-mRNA signal compared to tumors with normal H3K36me3 levels. To quantify
this effect, we calculated Intron Retention Scores (IRS), which reflect the ratio of intronic to
exonic RNA-seq reads on a gene-by-gene basis for each tumor. IRS values range from 0 to 1,
where a score of 0 represents a completely spliced message and a score of 1 represents uni-
form genic coverage. Intron retention was dramatically increased in the H3K36me3-deficient
tumors at 95% of the transcripts (6,551 in total) marked by H3K36me3 in normal kidney and
by nucleosome depletion (one-sided t-test, p < 0.01) in H3K36me3-deficient tumors (Figures
3.8A, 3.8C, 3.1B, 3.9A, 3.10). To confirm this result, we performed ChIP-seq from an in-
dependent normal kidney sample (Figure 3.9B). Of the 6,551 transcripts initially identified
(Figure 3.1 and Figure 3.8A), 6,101 were identified using the second normal kidney sample,
representing a 93% overlap. When the 6,551 transcripts by were instead stratified by PBRM1
mutation status, widespread intron retention was not observed (Figure 3.8B), suggesting this
effect is specific to tumors with H3K36me3 deficiency. Many of the affected genes are part
of recognized cancer-associated pathways, including known tumor suppressors (e.g. MET,
PTEN, and TP53), genes in the DNA repair pathway (e.g. ATR, RAD50, POLN, and XRCC1),
cell cycle regulators (e.g. CCNB1, and CCND3), as well as numerous receptors and protein
kinases (e.g. BRAF, EGFR, PIK3CA, and TGFBR3) (Figure 3.11).
3.2.5 Widespread RNA processing defects linked with SETD2 mutations persist in the mature
RNA pool and are marked by altered chromatin accessibility
To test whether the changes in pre-mRNA transcripts persisted into mature polyadenylated
RNA, we analyzed TCGA RNA-seq data derived from polyA+ mRNA from a large cohort
(n=416) of ccRCC tumors. Applying a gene-model-independent algorithm for read mapping
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Figure 3.8: H3K36me3 deficiency is associated with intron retention. Intron Retention Scores
for selected genes (Figure 3.1C) were compared between A. H3K36me3-deficient tumors and
H3K36me3-normal tumors, and B. PBRM1-mutant and PBRM1-normal tumors. C. Example
genes exhibiting increased intron retention in H3K36me3-deficient tumors (top, PPP2CB;
bottom, COX6C). Intron retention scores, genic coverage (calculated with both intron and
exon reads), and exonic coverage (calculated only with exonic reads) are provided for two
H3K36me3-deficient tumors (red) and two H3K36me3-normal tumors (black).
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Figure 3.9: H3K36me3-deficient tumors display increased intron retention compared to
H3K36me3-normal tumors. A. The number of RefSeq transcripts is plotted for each gra-
dation of Intron Retention Score (IRS) in rRNA-depleted RNA. An average intronic retention
score of 0 indicates exclusively exonic coverage (fully spliced) whereas an intronic retention
score of 1.0 indicates uniform genic coverage (the absence of exonic enrichment). B. Intron
Retention Scores for selected genes (Figure 3.1C) (however H3K36me3 ChIP-seq data was
obtained from normal kidney of a second individual) were compared between H3K36me3-












































Figure 3.10: GAPDH exhibits low intron retention in H3K36me3-deficient tumors. For
GAPDH, a gene not exhibiting increased intron retention in H3K36me3 deficient tumors,
intron retention scores, genic coverage (calculated with both intron and exon reads), and exon
coverage (calculated only with exonic reads) are provided for two H3K36me3 deficient tumors
(red) and two H3K36me3 normal tumors (black).
alterations in transcript processing (3929 transcripts, Figure 3.12A–B). Alterations included
intron retention (12% of altered transcripts, Figures 3.1B, 3.13), variation in exon utiliza-
tion (66% of altered transcripts, Figures 3.12B–C, 3.14), and differences in transcriptional
start and termination site usage (22% of altered transcripts). We also observed the generation
of previously unannotated splice isoforms, which we validated by quantitative PCR in inde-
pendent tumor samples (Figure 3.12D). Aberrancies in RNA processing were detected more
frequently in highly expressed genes (Figure 3.15A). Low abundance messages may preclude











































































































Figure 3.11: Enriched ontologies among genes with increased intron retention. Genes
(n=2999) exhibiting increased intron retention between in H3K36me3-deficient tumors
were assessed for associated ontologies. The most highly enriched terms among the
SP PIR KEYWORDS ontology are presented as the -log10 of the Bonferroni-corrected p-
value. P-values were filtered to p < 1 x 10-10. “Alternative splicing” refers to genes previously
annotated as exhibiting alternative splicing.
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exhibiting defects in RNA processing was comparable, however, between SETD2-mutant and
SETD2-normal tumors (Figure 3.15B). Increased intron retention and altered splicing were
additionally found more frequently in longer genes and genes with a larger number of exons
(Figure 3.16A–B).
Since H3K36me3 preferentially marks well-positioned exonic nucleosomes [171] [173]
[174], we analyzed chromatin accessibility around the intron-exon boundary of misspliced
exons. Tumors with normal levels of H3K36me3 demonstrated an expected reduction of
FAIRE signal immediately downstream of intron/exon junctions as well as a concomitant en-
richment in H3K36me3 (from ChIP-seq in normal kidney), indicative of a well-positioned
exonic nucleosome (Figure 3.12E, left), corroborating previous reports [173]. Strikingly, in
H3K36me3-deficient tumors, evidence of the exonic nucleosome was lost and a dramatic
increase in chromatin accessibility was observed immediately upstream (50 bp) of the in-
tron/exon junction (Figure 3.12E, left, red line). This pattern was also evident, though less
pronounced, at internal exon start sites of random genes (Figure 3.12E, middle) but com-
pletely absent at random genic positions (Figure 3.12E, right). Changes in chromatin accessi-
bility even at internal exons chosen regardless of whether they exhibited a splicing defect may
indicate a more widespread defect that may not always result in detectable variation in splic-
ing. These data demonstrate the ability to detect subtle variations in chromatin organization
in primary human tumors and link H3K36me3 loss with alterations in chromatin accessibility
at exons.
3.3 Discussion
To identify the genomic consequences of mutated chromatin regulators, we modified and
applied FAIRE-seq to a large cohort of primary kidney tumors. Using an unbiased approach,
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Tumor-specific open chromatin corresponded to HIF-targeted sites and was linked to genes
involved in the hypoxia response. This result reflects the well-studied association of ccRCC
development with VHL inactivation and HIF stabilization. These data also serve to validate
the use of FAIRE in primary tumors to detect biologically meaningful pathways.
We then associated variation in chromatin accessibility with mutations in chromatin reg-
ulators. Focusing on SETD2, we observed widespread increases in chromatin accessibility
especially in gene bodies typically harboring H3K36me3 in normal kidney tissue. A recent
report suggested that SETD2 silencing in cultured cells results in alternative internal transcrip-
tional start sites [177], akin to cryptic initiation observed in yeast [185] [186]. Our data using
human tumor specimens supports a more diverse model for transcriptional defects, including
retention of introns, missplicing of exons, and usage of alternative transcriptional start or end
sites. These defects were widespread, affecting nearly 25% of all expressed genes, and defects
were more common in highly transcribed genes.
Moreover, we found a surprising increase in chromatin accessibility immediately upstream
(50 bp) of misspliced exons in SETD2-mutated tumors. This result suggests a mechanism by
Figure 3.12: Widespread RNA processing defects linked with SETD2 mutations persist in
the mature RNA pool and are marked by altered chromatin accessibility. A. Splicing dif-
ferences (see methods) between SETD2-mutant and SETD2-normal tumors (red) compared
to a permuted control (blue) are plotted as a cumulative distribution function. B. Signifi-
cance of the difference in ratios between SETD2-mutant and SETD2-normal tumors (x-axis)
plotted against the scrambled control (y-axis). Points are colored by the class of RNA pro-
cessing aberrancy. A gray box represents significance (p = 0.01) in the SETD2 mutant-normal
comparison, but not significant in the control comparison. The percentages of significant dif-
ferences in transcript processing are also presented. C. Schematic of AP2A1 splicing. Exon
skipping was represented as the ratio of included exon coverage to the sum of the exon and the
spliced form. The skipped exon ratio is provided for SETD2-mutant tumors (red) and SETD2-
normal tumors (black). D. Quantitative PCR across two USH1C alternative exon utilization
sites identified by RNA-seq for three SETD2-normal tumors (black) and two SETD2-mutant
tumors (red). Error bars represent standard error. E. FAIRE signal plotted around the exon
start (within 3kb) of misspliced exons (left), random internal exon starts (middle), and random
genic positions (right) for H3K36me3-deficient tumors (red) and H3K36me3-normal tumors
(black). H3K36me3 ChIP-seq signal from normal kidney tissue is plotted in gray.
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Figure 3.13: Intron retention in SETD2-mutant tumors persists into mature, polyadenylated
RNA. Intron retention scores for 6,546 RefSeq transcripts in polyA+ RNA from the TCGA
dataset were averaged across two SETD2-mutant tumors and compared to that of three SETD2-
normal tumors. These tumors were selected based on their inclusion and analysis in both
datasets. These transcripts were marked by H3K36me3 in normal kidney and contained a site
determined by FAIRE to be more nucleosome-depleted in H3K36me3-deficient tumors.
70
-log10 (p-value)


















2 4 6 8 10
-log10 (p-value)


















2 4 6 8 10
-log10 (p-value)


















2 4 6 8 10
-log10 (p-value)


















2 4 6 8 10
All Intron Retention
Alternate TSS/TTS Alternative splicing
Figure 3.14: SETD2-mutant tumors display widespread changes in RNA processing. Signif-
icance of the difference in ratios between in SETD2 mutant and normal tumors (x-axis) are
plotted against the scrambled control (y-axis). Combined instances of altered transcript pro-
cessing (black) can be subdivided as intron retention (blue), alternate transcriptional start or










First quartile (top 25%)
Fourth quartile (bottom 25%)
Second quartile
Third quartile
True SETD2 mutant vs normal
p < 0.01














































































Figure 3.15: Aberrant splicing is preferentially detected in highly transcribed genes. A. RNA
abundance for each gene was averaged across all tumors and normal kidney then divided into
quartiles. We detected differences in splicing in approximately 38% of the first quartile of
genes (top 25% of genes by expression), but only about 8% of genes in the fourth quartile
(bottom 25% of genes by expression). B. Overall RNA levels (RPKM) for SETD2-mutant
(n = 38, marked in red) and SETD2-normal tumors (n = 380, marked in black), showing that
the expression of genes with defective RNA processing is comparable between these tumor
classes.
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Figure 3.16: Aberrant splicing and intron retention is preferentially detected in long genes and
genes with more exons. A. log10 gene length (bp) is plotted for genes with increased IRS in
H3K36me3-deficient tumors (left panel, left) and genes with decreased IRS in H3K36me3-
deficient tumors (left panel, right). log10 gene length (bp) is plotted for genes with altered
splicing (p < 0.01) in SETD2-mutant tumors (right panel, left) and genes without altered
splicing (p > 0.01) in SETD2-mutant tumors (right panel, right). B. Exon count is plotted
for genes with increased IRS in H3K36me3-deficient tumors (left panel, left) and genes with
decreased IRS in H3K36me3-deficient tumors (left panel, right). Exon count is plotted for
genes with altered splicing (p < 0.01) in SETD2-mutant tumors (right panel, left) and genes
without altered splicing (p > 0.01) in SETD2-mutant tumors (right panel, right).
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which the altered inclusion of the downstream exon is related to nucleosome positioning over
the exon itself as well as the adjacent upstream nucleosome. Nucleosome positioning and his-
tone modifications (including H3K36me3) are known to regulate multiple processes involved
with splicing, including changes in the speed or pausing of RNA polymerase [187] [188] [189]
[190] [191], and the ability for splicing machinery to appropriately recognize the splice donor
and acceptor. Our finding also suggests that the positioning of this upstream nucleosome
may be related to trimethylation of H3K36 on the exonic nucleosome. In S. cerevisiae, loss
of Set2 leads to destabilization of nucleosomes through hyperacetylation of gene bodies and
cryptic transcriptional initiation [185] [186]. Since hyperacetylation was not observed fol-
lowing SETD2 silencing [171], the increased chromatin accessibility we observed over gene
bodies may therefore represent nucleosome destabilization in a hyperacetylation-independent
manner. Although our results directly link SETD2 mutation and H3K36 trimethylation to
chromatin accessibility, studies that specifically examine nucleosome positioning and histone
modification will be necessary to fully investigate this potential mechanism.
Though our data associate SETD2 mutations/H3K36me3 deficiency with aberrant RNA
processing, exactly how this dysregulation contributes to tumorigenesis remains unknown.
A significant fraction of the deregulated transcripts include known tumor suppressors, DNA
damage response proteins, and kinases. Strikingly, 58% of genes with altered splicing pat-
terns (Figure 3.12A–B) encode annotated phosphoproteins (p = 7.3 x 10-109), representing an
enrichment exceeding that of genes annotated as having alternate splice isoforms (p = 2 x
10-60), a finding also observed in genes exhibiting retained introns (Figures 3.11, 3.17). Alter-
ations in the abundance, stability, or splicing of RNA could induce changes in the phosphopro-
teome and disrupt normal cellular signaling and growth checkpoints, leading to tumorigenesis.
Deregulated signaling as well as transcriptional defects provide numerous putative targets for
therapeutic exploitation. Additionally, the application of FAIRE, or IHC for H3K36 trimethy-
lation, could enable the classification of clinical specimens into functional tumor subtypes.


























































































































































Enriched SP_PIR_KEYWORDS in misspliced genes
Figure 3.17: Enriched ontologies among misspliced genes. Genes exhibiting significant
splicing differences between SETD2 mutant and normal tumors (p < 0.003) in the TCGA
cohort were assessed for associated ontologies. The most highly enriched terms in the
SP PIR KEYWORDS ontology are presented as the -log10 of the Bonferroni-corrected p-
value. P-values were filtered to p < 1 x 10-3. “Alternative splicing” refers to genes previously
annotated as exhibiting alternative splicing.
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fecting chromatin organization and alterations in transcription. RNA processing defects in
a large fraction of expressed genes, many of which are tumor-suppressors critical for cellu-
lar function, may be a common phenotype of many cancers. Comprehensive mapping of the
chromatin landscape in primary tumors offers a new tool for understanding the functional
consequences of chromatin modifier mutations in human disease.
3.4 Methods
3.4.1 Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE-seq) and hierarchical
clustering of differentially open chromatin
FAIRE was performed as previously described [74] [75]. Sequencing was performed us-
ing 36- or 50-bp single-end reads (Illumina GAIIx or HiSeq 2000). Reads were filtered using
TagDust [192] and aligned to the reference human genome (hg19) with Bowtie [193] us-
ing default parameters. Reads were counted in 500 bp sliding windows across the genome,
normalized for sequencing depth, and adjusted for batch effects using Principal Components
Analysis (PCA). One outlier normal kidney sample was removed at this step, and all normal
kidney samples were removed for subsequent tumor-only analyses. For clustering analyses,
only windows with sufficient sequencing depth (row average > 0.25) were retained; groups
were compared using 1- or 2-sided t-tests (p < 0.01), clustered and plotted [156]. Feature
intersections were computed using BEDtools [154].
3.4.2 Re-processing of HIF1A, HIF2A, and ARNT ChIP-seq data
ChIP-seq reads for HIF1A, HIF2A, and ARNT [180] were filtered using TagDust [192]
and aligned to the reference human genome (hg19) using Bowtie [193] requiring unique read
placement. Binding sites (q < 0.05) for HIF1A and HIF2A were identified using MACS
[194], with a shift-size of 250 bp.
76
3.4.3 Ontologies associated with differentially open chromatin
Regions from Clusters 1–3 were associated with gene ontologies using GREAT [118]
using all possible 500 bp windows as background. The top 5 ontologies with q < 1 x 10-5
were presented; full gene ontology associations are supplied in Figure 3.5.
3.4.4 Motif analysis
Significantly over-enriched known Transcription Factor (TF) motifs were identified using
HOMER [181]. The 500 bp flanking region was used as local background. Only those TF
motifs whose enrichment over background exceeded 2.5-fold, were present in at least 10%
of the target sequence, and q < 0.0001 were presented in Figure 3.2D. Highly similar entries
were merged.
3.4.5 SureSelect custom capture and mutation calling
Genotyping was performed using the SureSelect XT Custom Capture (Agilent). Multi-
plexing was achieved using TruSeq adapters (Illumina); samples were pooled prior to the
capture and amplified post-capture using TruSeq PCR primers (Illumina). Blocking reagents
were replaced with water to avoid cross-reactivity. Sequencing was performed using 50-bp
paired-end reads (Illumina HiSeq 2000). Reads were aligned to the reference human genome
(hg19) using BWA [193]. Genes were sequenced to an average coverage of 200X with 85%
of the target sequenced to least at 50X. Genotypes were determined using the Genome Anal-
ysis Toolkit (GATK) [195] “Better” protocol. Only high-confidence (quality score > 100)
variants predicted to have high or moderate severity and not reported in dbSNP (v129) were
considered.
3.4.6 Histone methylation ChIP-seq and data processing
ChIP for H3K36me3 and input DNA from normal kidney was sequenced on the Illumina
GAII. Reads were aligned to the reference genome (hg19) using Bowtie requiring unique
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alignment. H3K36me3 sites were called first using ZINBA [110], then merged to call broader
domains by merging two or more nearby (within 5 kb) sites using Galaxy [155]. The average
H3K36me3 signal across gene bodies was plotted using CEAS [153].
3.4.7 Feature overlap permutations
Significance of overlap between sites of differentially open chromatin associated with
SETD2 or PBRM1 mutations and H3K36me3 sites was determined by permutation. First,
the overlap between the actual set of significant windows and histone methylation was com-
puted. Then the same number of randomly-selected windows from the full list (regardless of
significance) was selected 1000 times, and an empirical p-value was determined by counting
the number of times the overlap of the permuted set exceeded that of the actual set.
3.4.8 Tissue Microarray Construction and Immunohistochemistry
Tissue microarrays (TMAs) were constructed from formalin-fixed, paraffin-embedded tu-
mor blocks from 69 ccRCC tumors and 11 matched normal kidneys collected at the time of
nephrectomy. Hematoxylin and eosin stained slides were reviewed to identify a target area
of ccRCC histology in each tissue block. TMAs were then constructed using 0.6 mm cores
on the manual tissue microarrayer (Beecher Instruments). Tumor and normal samples were
represented in triplicate. Sequential 4 µm slides were cut from each TMA.
Immunohistochemical (IHC) staining of H3K36me3, of Histone H3, and SETD2 was per-
formed (Bond Autostainer, Leica Microsystems, Inc.) according to the manufacturer’s proto-
col. Antigen retrieval for H3K36me3, SETD2 and Histone H3 was performed for 30 minutes
in Citrate Buffer pH 6.0 (Bond AR9961) and hydrated with Bond wash buffer (AR9590).
Slides were incubated with H3K36me3 antibody (Abcam, ab9050, dilution 1:2000) or His-
tone H3 (courtesy of the Strahl Lab, dilution 1:5000) or SETD2 (Abcam, ab31358, 1:200) for
1 hour at room temperature. Antibody detection was performed (Bond Polymer Refine Detec-
tion System, DS9800) followed by image acquisition (ScanScope CS, Aperio Technologies).
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Quantification of H3K36me3, SETD2, and Histone H3 was performed independently by
two reviewers who were blinded to the tissue identity. The percentage of tumor cells with
positive nuclei was determined by evaluating the entire core for each sample. The degree
of H3K36me3 or SETD2 staining was averaged across triplicate samples and normalized to
total H3 to correct for differences in cell number. Using the minimum value of normalized
H3K36me3 in normal kidney as a cutoff, tumors were stratified as either “H3K36me3-normal”
or “H3K36me3-deficient” for subsequent analyses. Five additional tumors (not represented
on the tissue microarray) were similarly assessed by immunohistochemistry and classified as
“H3K36me3-deficient” (3 tumors) or “H3K36me3-normal” (2 tumors).
3.4.9 Intron retention estimates by RNA-seq
Total RNA was isolated from tumors (miRNeasy, Qiagen) and validated to have a median
RNA Integrity Numbers (RIN) of 8.6 (minimum 6.8) using a Bioanalyzer (Agilent). Riboso-
mal RNA was depleted (RiboMinus, Invitrogen) and RNA was fragmented (RNA Fragmenta-
tion Reagents, Ambion). cDNA was generated (SuperScript II, Invitrogen) by random priming
followed by second strand synthesis (DNA Polymerase I, Enzymatics) and purified (PCR pu-
rification kit, Qiagen). Libraries were prepared according to the manufacturer’s specifications
(Illumina). Sequencing was performed using 50-bp single-end reads (Illumina HiSeq 2000).
Reads were aligned to the reference human genome (hg19) using TopHat [196] and gene ex-
pression was estimated by calculating RPKM, analyzing only exonic reads. Intron Retention
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3.4.10 Quantitative RT-PCR
Total RNA extracted from patient tumors (Qiagen miRNeasy) was either rRNA-depleted
(Ribo-Minus, Invitrogen) or polyA-selected (Oligotex mRNA Mini Kit, Qiagen). RNA was
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reverse transcribed by random priming (Supercript II Reverse Transcriptase, Invitrogen) and
cDNA was quantified by PCR and normalized to ABCF (Maxima SYBR Green/ROX qPCR







3.4.11 Differential splicing analysis
RNA-seq reads were aligned to the human reference genome using MapSplice [197]. For
each gene, a splicing graph was created as previously described [184]. Each exon and splic-
ing event was represented as an edge, and splice junctions as nodes. We computed a splicing
fraction of each edge as the fraction of RNA-seq coverage in that edge divided by the total
coverage of all edges sharing one node of that edge. Only edges with coverage exceeding 5
reads and genes with multiple isoforms (13,879 genes) were considered. The node exhibiting
the largest difference between SETD2 mutant and normal tumors was determined by compar-
ing the median of each group. As a control, we created random groups of tumors of the same
sizes. Splicing differences between SETD2 mutant and normal tumors were compared to that
of the control group by a Kruskal-Wallis one-way analysis of variance test. The skipped exon
ratio was computed as the ratio of coverage of the included exon, and sum of coverages of the
included exon and the skipping splice.
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CHAPTER 4
ISOLATION OF REGULATORY ELEMENTS FROM ARCHIVAL HUMAN
SPECIMENS USING FAIRE
4.1 Introduction
Archiving biopsy and other tissue samples in paraffin following extended formalin fix-
ation (Formalin-Fixed Paraffin Embedded, FFPE) is the standard pathological procedure in
hospitals and biobanks. It is estimated that over 1 billion of these samples exist worldwide
[198]. The ability to store specimens long-term at room temperature and later assess cellular
histology, as well as the relative ease and low cost of use leads to the predominant prefer-
ence for FFPE archiving over flash-freezing tissues in liquid nitrogen and storing them at
-80◦C. FFPE-archived specimens, however, have undergone significant manipulations to en-
sure their histological integrity for long periods of time. After resection or biopsy, the tissue is
placed in neutral-buffered formalin (consisting of 3–4% formaldehyde) for 4–48 hours. After
fixation, the tissue is gradually dehydrated, passing through a series of graded ethanols and
xylenes, then finally embedded in paraffin wax. This process, particularly the extended fixa-
tion time, can lead to nucleic acid degradation and modification or damage to DNA through
formaldehyde-induced adducts [199].
It has recently been discovered that a modified preparation of chromatin for immunopre-
cipitation from FFPE (PAT-ChIP) results in similar genome-wide profiles of histone modifica-
tions as fresh samples [200] [201]. These results indicate that despite the extended formalde-
hyde fixation, chromatin not only remained sufficiently intact to probe post-translational mod-
ifications of histone proteins, but also was amenable to detection by quantitative PCR and
high-throughput sequencing.
An alternative method of studying chromatin organization is Formaldehyde-Assisted Iso-
lation of Regulatory Elements (FAIRE), which utilizes a short fixation time to ensure only
histone-DNA interactions are crosslinked [166] [72] [73]. FAIRE has been used extensively
to study accessible regions of chromatin in a multitude of eukaryotic cells and tissues [15]
[54] [76] [78] [77] [57], and has proven effective at identifying tumor-subtype-specific dif-
ferences in chromatin accessibility that were linked to RNA processing defects (Chapter 3)
[202]. The extended fixation imparted by FFPE preparation, however, could damage and/or
over-fragment nucleosome-free DNA or otherwise hinder our ability to identify regulatory
elements from these tissues.
Here, we set out to explore whether a modified FAIRE procedure could allow us to over-
come these technical challenges and detect biologically relevant regulatory elements from
FFPE human tumors. In a highly controlled system that permits the direct comparison of
cultured cells, frozen tissue, and FFPE tissue, we show that deparaffinization and rehydration
of 10-µm FFPE sections prior to lysis, sonication, and phenol-chloroform extraction leads to
the highly concordant detection of both promoter-proximal and distal locations of nucleosome
depletion. Moreover, we demonstrate that FFPE-FAIRE is robust to as few as 1 x 106 cells, a
quantity easily achievable from most specimens. Ongoing work will investigate whether the
type, (e.g. carcinoma, sarcoma, blastoma), location (e.g. brain, breast, kidney, bone), or age
of the FFPE tumor sample (upwards of 20 years old) plays a role in our ability to identify
biologically relevant regions of chromatin accessibility. If successful, this approach will ulti-
mately allow us to follow the effects of cancer therapies longitudinally in single patients, as
well as perform large-scale studies of rare diseases. Moreover, its potential clinical relevance
could allow for the employment of FAIRE as a high-throughput clinical diagnostic.
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4.2 Results
4.2.1 FFPE-FAIRE shows high concordance with frozen tissue and cultured cells in controlled
xenograft system
We began our study utilizing a tumor-derived cancer cell line (EWS894). Cells were sub-
cutaneously injected into two NOD scid gamma (NSG) mice to form tumors. Upon resection,
tumors from both mice were divided; half of the portions were flash-frozen in liquid nitrogen
and stored at -80◦C whereas the other half were crosslinked in neutral-buffered formalin for
4–6 hours. Portions of tumors from each mouse were then co-embedded in paraffin (FFPE)
as per standard pathological procedures. For FFPE specimens, 10-µm sections were deparaf-
finized and gradually rehydrated, then lysed, sonicated, and subject to phenol/chloroform ex-
traction as previously described (Figure 4.1a). FAIRE-seq was performed as previously de-
scribed for cultured cells as well as frozen xenografts [74] [75]. We then compared the open
chromatin landscape of EWS894 among cultured cells, frozen tissue, and 1 x 106 cell equiva-
lents of FFPE tissue following high-throughput sequencing (Figure 4.1b–e). We found that, in
general, there was consistent FAIRE enrichment across all three sample sources at promoter-
proximal regions (Figure 4.1b), and that this enrichment correlated with gene expression, as
has been previously shown [74] (Figure 4.1d). We also assessed FAIRE enrichment around
binding sites for CTCF (Figure 4.1c) as well as a class of distal regulatory elements (GGAA
microsatellite repeats) bound in this form of cancer by a translocation-derived transcription
factor chimera, EWS-FLI [57] (Figure 4.1e). Although the FAIRE signal at these two classes
of distal regulatory elements was somewhat reduced in FFPE tissue (Figure 4.1c, e), a high
degree of correlation (Pearson r = 0.78) between frozen and FFPE tissue was nonetheless ob-
served at EWS-FLI-bound GGAA microsatellite repeats, likely the most biologically relevant
class of regulatory element in this cell type (Figure 4.1e).
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4.2.2 FFPE-FAIRE is robust to as few as 1 x 106 cells
We next wanted to explore the degree to which starting material quantity affects FAIRE
signal. In addition to 1 x 106 cell equivalents (Figure 4.1), we also performed FAIRE from
5 x 105, 2 x 106, 1 x 107, and 2 x 107 cell equivalents from the same FFPE specimen. Sur-
prisingly, we observed a decline in the signal-to-noise as the amount of starting material in-
creased. Moreover, we observed poor library complexity in the sample corresponding to 5 x
105 cell equivalents (94% of reads aligned to a non-unique start coordinate; only 35% of reads
aligned to non-unique start coordinates for 1 x 106 cell equivalents) (Figure 4.2). To quantify
these differences, we developed a novel metric termed the Chromatin Integrity Number (ChIN
score), akin to an in silico quantitative PCR experiment. Based on calculations on cell lines
and tissues assayed as part of ENCODE [54], ChIN scores in excess of 0.8 have sufficient
signal-to-noise at the five positive control loci tested. ChIN scores maintained stable, as did
correlations of signal between frozen and FFPE tissue, from 1–2 x 106 cell equivalents, but
both declined as starting material increased to 1–2 x 107 (Figure 4.2).
4.2.3 Ongoing work
We will soon be scaling up to assay chromatin accessibility across a cohort of 15 patients
with diverse forms of cancer: clear cell Renal Cell Carcinoma, luminal and basal-type breast
carcinoma, medulloblastoma, and Ewing Sarcoma. This will allow us to investigate whether
Figure 4.1: FFPE-FAIRE shows high concordance with frozen tissue and cultured cells in
controlled xenograft system. a. Experimental schema. Deparaffinization and rehydration of
10-µm FFPE sections prior to lysis, sonication, and phenol-chloroform extraction permit the
isolation of regulatory elements from FFPE tumor chromatin. b. UCSC Genome Browser
screenshot demonstrating high promoter-proximal concordance among sample source types.
c. Normalized FAIRE signal from fresh cells (black), frozen tissue (red), and FFPE tissue
(blue) around CTCF binding sites identified by ChIP-seq in endothelial cells [14]. d. Heatmap
of normalized FAIRE signal 3 kb around TSS ranked by gene expression in Ewing cells. Color
was assigned on a log2 scale of -3 to 1. e. FAIRE signal over EWS-FLI-bound (red) and EWS-
FLI-unbound (black) GGAA microsatellites is highly concordant (Pearson r = 0.78) between
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Figure 4.2: FFPE-FAIRE is robust to as few as 1 x 106 cells. UCSC Genome Browser screen-
shot of FAIRE signal from fresh cells (black), frozen tissue (red), and FFPE tissue (blue).
Varying FFPE section thickness allowed for the isolation of DNA from a wide range of start-
ing material quantity, from 5 x 105 to 2 x 107 cell equivalents. Two technical replicates were
performed for 2 x 107 cell equivalents.
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the type, (e.g. carcinoma, sarcoma, blastoma), location (e.g. brain, breast, kidney, bone), or
age of the FFPE tumor sample (upwards of 20 years old) plays a role in our ability to identify
biologically relevant regions of chromatin accessibility. We will compare FAIRE enrichment
in a comprehensive manner between frozen and FFPE tissue for 10 of these tumors, assay-
ing generic promoter-proximal and distal regions, as well as regions relevant to each tumor
type (e.g. GGAA microsatellites, Ewing Sarcoma; HIF binding sites, Renal Cell Carcinoma;
estrogen receptor (ER) binding sites, luminal subtype breast carcinoma). Additionally, geno-
type and gene expression data have been gathered for many of these samples; this information
can be utilized to link cancer-type-specific differences in chromatin accessibility with cancer-
type-specific differences in gene expression.
4.3 Discussion
We report here a modification to the Formaldehyde-Assisted Isolation of Regulatory El-
ements (FAIRE) procedure for use on Formalin-Fixed Paraffin-Embedded (FFPE) tissue to
utilize clinically annotated human specimens available in hospitals and biobanks worldwide.
In a highly controlled xenograft system, we directly compared chromatin accessibility from
cultured cells, frozen tissue, and FFPE tissue. We showed that both promoter-proximal and
distal locations of nucleosome depletion were highly concordant among these tissue sources.
Moreover, we investigated whether the quantity of starting material affected FAIRE signal and
whether there was a lower limit for detection of accessible regions of chromatin from FFPE
samples. We demonstrated that FFPE-FAIRE is robust to as few as 1 x 106 cells, a quantity
easily achievable from most specimens, but FAIRE-seq library complexity degraded signifi-
cantly with 5 x 105 cells. Ongoing work will investigate whether the type, location, or age
of the FFPE tumor sample plays a role in our ability to identify biologically relevant regions
of chromatin accessibility and tumor-type-specific differences in chromatin accessibility that
coincide with differences in gene expression or genotype.
Our results demonstrate that despite numerous technical challenges, the modified FAIRE
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technique allows for the detection of many biologically relevant regulatory elements from
FFPE tumor chromatin. This approach will ultimately enable novel studies of rare diseases,
molecular consequences of therapeutic intervention, and pharmacological efficacy using chro-
matin accessibility as a readout. Additionally, we have already shown that when coupled with
robotics, FAIRE can be used in an automated manner to screen small molecules designed
to inhibit chromatin regulators, and that lead compounds from the screen confer inhibition
of tumor cell growth in soft agar, a hallmark of oncogenic transformation [Pattenden et al,
manuscript in preparation]. If similarly coupled with robotics, FFPE-FAIRE could be used
in automated screens of small molecule inhibitors to both prospectively and retrospectively
identify the best course of therapeutic action across hundreds to thousands of patients simul-
taneously.
4.4 Methods
4.4.1 Xenograft model and estimation of tumor nuclei density
Approximately 5 x 106 cancer cells (EWS894) were subcutaneously injected using ma-
trigel bilaterally into two NOD scid gamma (NSG) mice (JAX laboratories) to form tumors.
Upon resection, tumors from both mice were divided; half of the portions were flash-frozen
in liquid nitrogen and stored at -80◦C whereas the other half were crosslinked in neutral-
buffered formalin for 4-6 hours. Portions of tumors from each mouse were then co-embedded
in paraffin (FFPE) as per standard pathological procedures. Hematoxylin and Eosin staining
was performed on the Leica Autostainer XL from 5-µm FFPE sections. Nuclei counts were
estimated by Definiens Tissue Studio version 3.5.1. Paraffin embedding, sectioning, staining,
and nuclei count estimates were performed by the UNC Translational Pathology Laboratory.
4.4.2 FFPE-FAIRE
For FFPE specimens, 10-µm sections were deparaffinized in six consecutive 10-minute
washes (rocking at room temperature) in 1 mL BiOstic deparaffinization solution (MO-BIO
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Laboratories, Carlsbad, CA), each followed by centrifugation at 20,000 x g for 2 minutes at
room temperature. The pellets were then gradually rehydrated through graded ethanols (1 mL
of 100%, 95%, 70%, 50%, 20%, 0% ethanol), each rocking for 5 minutes at room temperature
followed by centrifugation at 20,000 x g for 2 minutes at room temperature. The final rehy-
drated pellets were then resuspended in 1 mL FAIRE lysis buffer and lysed by bead-beating,
sonicated, and subjected to phenol/chloroform extraction as previously described [74] [75].
FAIRE-seq libraries were prepared for sequencing using TruSeq barcoded adapters as per
manufacturers instructions (Illumina), and sequenced as single-end 50-bp reads. Reads with
significant adapter contribution were removed using TagDust [192] and assessed to ensure
their high quality using the FASTX-Toolkit. Reads from frozen and FFPE tissues were first
aligned to the reference mouse genome (mm9) using Bowtie [203] [152] to remove any murine
contamination. Non-mouse reads were then aligned to the reference human genome (hg19)
using Bowtie, allowing for two mismatches and reads to align to up to four locations in the
genome, though only the best-scoring alignment was used. Data visualization was achieved
using the UCSC Genome Browser .
4.4.3 Reanalysis of EWS-FLI binding sites and GGAA microsatellites
EWS-FLI ChIP-seq data from a Ewing Sarcoma cell line (EWS502) was aligned and re-
analyzed as was previously described [57], except to the reference human genome (hg19).
GGAA microsatellites defined by RepeatMasker were divided based on their EWS-FLI bind-
ing status using BEDtools [154]. Signal at GGAA microsatellites was calculated based on the
number of reads overlapping the repetitive element, normalized by total sequencing depth.
4.4.4 ChIN score calculation
FAIRE signal was computed at 500-bp windows near the TSS (positive controls) of five
genes (MBOAT7, CNOT3, BC006361, AURKIP1, EIF3F) as well as nearby 500-bp negative
control windows. The ChIN scores were then calculated as:
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Σ signal at positive controls
Σ signal at positive controls + Σ signal at negative controls
Scores range from 0 to 1, where ChIN scores closest to 1.0 represent samples with optimal
signal-to-noise. ChIN scores greater than 0.8 were considered to have sufficient quality.
The genomic coordinates (hg19) utilized to calculate ChIN scores are as follows:













CONCLUSIONS AND FUTURE DIRECTIONS
The advent of high-throughout DNA sequencing enabled many large-scale studies of mu-
tation types and frequencies across thousands of cancer classes. An emerging theme is that
genes that encode chromatin regulators are frequent, but also disproportionately prevalent in
pediatric and hematological malignancies. The molecular consequences of chromatin regu-
lator mutations on a genome-wide scale, and moreover, how other genetic insults drive chro-
matin dysregulation and potentially enhance tumorigenesis, were until now completely un-
known. The preceding work leveraged two model cancer systems, Ewing Sarcoma and clear
cell Renal Cell Carcinoma, through which we were able to better understand the causes and
consequences of chromatin dysregulation.
In Ewing Sarcoma, a fusion oncoprotein (EWS-FLI) is formed as a result of a chromo-
somal translocation. This transcription factor chimera exhibited altered binding properties
when compared to its DNA-binding parental protein FLI1 despite identical ETS-family DNA
binding domains. Instead of localizing to canonical ETS motifs, EWS-FLI bound a subset
of microsatellite repeats, ones that contain a multimerization of the GGAA core of the ETS
sequence motif. We found that this differential targeting was influenced by epigenetic factors.
These microsatellite regions were atypically marked with an enhancer-like signature, were
bound by RNA polymerase II, and resided in nucleosome-depleted regions. Our data suggest
that the chromatin-modifying activity conferred to EWS-FLI through chimerism is necessary
and sufficient to alter the local chromatin landscape. The observation of widespread FAIRE
enrichment of repetitive regions may also suggest that a favorable chromatin landscape per-
missive of EWS-FLI targeting may exist in the likely cell type of origin (mesenchymal stem
cells), a question currently being explored.
Transcription factors themselves have long been believed to be undruggable for several
reasons. First, designing small molecule inhibitors that block DNA-binding activity with any
specificity is difficult due to sequence and structural properties shared among many transcrip-
tion factors or transcription factor families. Second, in cases such as c-Myc, the transcription
factor carries out many functions, only a subset of which are oncogenic, meaning the ther-
apy would need high specificity toward cancerous cells to avoid potent off-target effects. The
fact that EWS-FLI not only acts as a potent transcription factor but carries with it chromatin-
modifying activity creates an exciting and novel therapeutic window. If, through the use of
small molecules, we can revert the EWS-FLI-bound sites to a nucleosomal state, then perhaps
its stunted potency would specifically inhibit cancer cell viability.
This is currently the main focus question of an ongoing study in our lab. We hypothesized
that a drug-induced inhibition of chromatin-modifying activity would echo that of EWS-FLI
silencing by siRNA, as we saw using FAIRE-qPCR in Figure 2.21C. We therefore designed
a novel screen in which we could probe changes in chromatin accessibility, specifically at
EWS-FLI-bound genomic loci but not other regions, after the administration of one of nearly
1,000 chemical probes designed to inhibit various epigenetic modifiers. Due to the scale of
the experiment, traditional phenol-chloroform-based FAIRE would not be a suitable approach
to measure chromatin accessibility. Instead, we modified the FAIRE procedure such that
organic extraction was replaced with a simple column-based purification. The new method
behaved almost identically to that of traditional phenol-chloroform-based FAIRE, but more
importantly, it was amenable to robotics and could be performed in 96-well plates. Using
column-based FAIRE-qPCR as a readout, this small molecule screen has yielded many in-
teresting lead compounds and compound classes. One such compound has now been shown
by our lab to inhibit growth in soft agar at low doses, a hallmark of anchorage-independent
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growth commonly exhibited by cancer cells, and at higher doses, drastically inhibit cell viabil-
ity. Moreover, preliminary data show that these cellular phenotypic changes occur much later
than the chromatin-based findings of the initial screen, suggestive of a high level of specificity
toward EWS-FLI-bound targets rather than a simple (but potent) cytotoxic. Our ability to
measure the direct effects of inhibition of epigenetic modifiers is an exciting and novel means
to discover and develop efficacious cancer therapies. This study is also exciting from a basic
research standpoint because lead compounds may shed light on specific EWS-FLI complex
members, a common goal that has been difficult to study due to the inherently poor complex
stability.
In addition to ascribing novel chromatin-modifying functions to fusion oncoproteins and
inhibiting those effects therapeutically, we also investigated how mutations in chromatin regu-
lators themselves alter the chromatin landscape, with the ultimate goal of understanding their
oncogenicity. We utilized clear cell Renal Cell Carcinoma for this study, a cancer that carries
several recurrent mutations in chromatin regulators, including modulators of histone methyla-
tion as well as nucleosome positioning. Despite their prevalence in human cancers, especially
pediatric and hematological malignancies (as discussed in Chapter 1), the functional conse-
quences of chromatin regulator mutations had not yet been investigated.
Again utilizing FAIRE, in combination with high-throughput genotyping and transcrip-
tomics, we probed 49 primary human tissue samples, including some matched tumor and nor-
mal kidney, and associated variation in chromatin accessibility with mutations in SETD2, the
histone H3 lysine-36 tri-methyltransferase. We observed widespread increases in chromatin
accessibility especially in gene bodies typically harboring H3K36me3 in normal kidney tissue.
Though we expected this chromatin-based effect to manifest itself in differences in transcript
abundance, we instead noticed a far more widespread phenotype. These genes marked by
H3K36me3 in normal kidney that exhibited alterations of chromatin in tumors, as well as
many other genes, exhibited RNA processing defects, specifically the retention of introns.
Since our data were generated from pools of total RNA, we sought to validate this phenotype
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in mature (polyA+) RNA, and in a much larger cohort of primary tumor samples analyzed by
The Cancer Genome Atlas. These data supported a more diverse model for transcriptional
defects, including retention of introns, missplicing of exons, and usage of alternative tran-
scriptional initiation or termination sites. These defects were widespread, affecting nearly
25% of all expressed genes, and defects were more common in highly transcribed genes.
Moreover, we found a surprising increase in chromatin accessibility immediately upstream
(50 bp) of misspliced exons in SETD2-mutated tumors. This result suggests a mechanism by
which the altered inclusion of the downstream exon is related to nucleosome positioning over
the exon itself as well as the adjacent upstream nucleosome. Nucleosome positioning and
histone modifications (including H3K36me3) are known to regulate multiple processes in-
volved with splicing, including changes in the speed or pausing of RNA polymerase [187]
[188] [189] [190] [191], and the ability for splicing machinery to appropriately recognize the
splice donor and acceptor. Our finding also suggests that the positioning of this upstream
nucleosome may be related to trimethylation of H3K36 on the exonic nucleosome. Although
our results directly link SETD2 mutation and H3K36 trimethylation to chromatin accessibil-
ity, studies that specifically examine nucleosome positioning and histone modification will
be necessary to fully investigate this potential mechanism. Experiments utilizing micrococal
nuclease (MNase) digestion to identify the exact positions of nucleosomes in and around mis-
spliced exon starts would further our understanding of the molecular mechanisms of the RNA
processing defects, but these experiments can not yet be easily performed in primary tumors.
Instead, we will leverage a new cell line model developed by our group in which SETD2
has been completely silenced through the use of TALENs. We have shown preliminarily
that SETD2-knockout cells lack H3K36me3 and exhibit some of the same RNA processing
defects. Future work with this model system will explore nucleosome positioning, spliceo-
some recruitment, and RNA polymerase binding and kinetics in the presence and absence of
SETD2/H3K36me3.
Though our data associate SETD2 mutations/H3K36me3 deficiency with aberrant RNA
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processing, exactly how this dysregulation contributes to tumorigenesis also remains un-
known. Whether the defects in processing lead directly to the inhibition of tumor suppres-
sors or the modulation or induction of oncogenes has not yet been investigated. Future work
again utilizing cultured cells with or without SETD2 perhaps in conjunction with a siRNA
screen may inform us as to which key genes, when either directly silenced by siRNA or in-
hibited through SETD2-knockout-induced RNA processing defects, govern critical cellular
processes.
Another means for better understanding the underlying tumorigenic behavior induced by
SETD2/H3K36me3 loss is through a synthetic lethality screen. If we can identify compounds
that specifically hinder the growth of cancer cells lacking SETD2, then perhaps they are help-
ing to reverse the induction of crucial oncogenes or the silencing of specific tumor suppressors.
This screen is a current focus of our lab, and we believe it will not only shed light on under-
lying biology, but also yield numerous lead compounds for the treatment of clear cell Renal
Cell Carcinomas harboring SETD2 mutation.
An additional important contribution is the ability to now probe chromatin accessibility
in Formalin-Fixed Paraffin-Embedded (FFPE) tissues. This tissue archiving technique is by
far the most common, as opposed to freezing tissue and storing at -80◦C, and is traditionally
used by pathologists in disease diagnosis by studying cellular morphology. Their massive
availability coupled with clinical annotations makes these specimens an attractive source of
biological material for use in numerous RNA- or DNA-based assays. The extended fixation
in formalin critical to this archiving process, however, is known to damage nucleic acids
in multiple ways. Despite the numerous technical barriers, we showed that both promoter-
proximal and distal locations of nucleosome depletion were highly concordant among cultured
cells, frozen tissue, and FFPE tissue in a highly controlled xenograft system. Moreover, we
found that there is a lower limit for detection of accessible regions of chromatin from FFPE
samples; FAIRE-seq library complexity degraded significantly with 5 x 105 cells but was
robust to 1 x 106 cells. Ongoing work will investigate whether the type, location, or age of
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the FFPE tumor sample plays a role in our ability to identify biologically relevant regions
of chromatin accessibility and tumor-type-specific differences in chromatin accessibility that
coincide with differences in gene expression or genotype.
This approach will ultimately enable novel large-scale studies of rare diseases, allow us
to understand the molecular consequences of therapeutic intervention, and both prospectively
and retrospectively identify the best course of therapeutic action across hundreds to thousands
of patients simultaneously. In addition, if data are obtained across many different forms of
cancer, we can design clinical diagnostics based on differentially accessible regions of chro-
matin, similar to how differential gene expression is currently used as a diagnostic in systems
such as breast cancer. Considerable efforts will be needed to not only identify the genomic re-
gions with largest diagnostic and prognostic power, but also design the algorithms with which
tumors can be assigned to a type and subtype de novo with extremely high specificity. Clin-
ical usage of FAIRE from FFPE material would also likely require significant improvements
to the methodology itself to permit its automation on a large scale. Future work will explore
the usage of specially designed 96-well plates to more quickly and efficiently deparaffinize
and rehydrate tissues prior to their lysis and downstream manipulations.
Together, these studies advance our understanding of chromatin dysregulation in cancer
in multiple aspects. We now better understand the relationship between genetic alterations
affecting chromatin organization and alterations in transcription, and moreover, RNA pro-
cessing defects mediated by chromatin or other means may be a common phenotype of many
cancers. We also discovered epigenetic alterations driven by a chimeric transcription factor,
which led to preliminary yet exciting new therapeutic avenues that reverse these chromatin-
modifying effects and inhibit cancer cell growth. Though much work will be needed, chro-
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